

Review Article

POTENTIAL ROLE OF FREE RADICALS IN BENZENE-INDUCED MYELOTOKICITY AND LEUKEMIA

VANGALA V. SUBRAHMANYAM,* DAVID ROSS,† DAVID A. EASTMOND‡ and MARTYN T. SMITH*

*Department of Biomedical and Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA 94720, U.S.A. †Molecular Toxicology and Environmental Health Sciences Program, School of Pharmacy, University of Colorado, Boulder, CO 80309, U.S.A. ‡Environmental Toxicology Graduate Program, Department of Entomology, University of California, Riverside, CA 92521, U.S.A.

(Received 4 February 1991; Revised and Accepted 10 June 1990)

Abstract—Occupational exposure to benzene, a major industrial chemical, has been associated with various blood dyscrasias and increased incidence of acute myelogenous leukemia in humans. It is established that benzene requires metabolism to induce its effects. Benzene exposure in humans and animals has also been shown to result in structural and numerical chromosomal aberrations in lymphocytes and bone marrow cells, indicating that benzene is genotoxic.

In this review we have attempted to compile the available evidence on the role of increased free radical activity in benzene-induced myelotoxic and leukemogenic effects. Benzene administration to rodents has been associated with increased lipid peroxidation in liver, plasma, and bone marrow, as shown by an increase in the formation of thiobarbituric-acid reactive products that absorb at 535 nm. Benzene administration to rodents also results in increased prostaglandin levels indicating increased arachidonic acid peroxidation. Other evidence includes the fact that bone marrow cells and their microsomal fractions isolated from rodents following benzene-treatment have a higher capacity to form oxygen free radicals.

The bone marrow contains several peroxidases, the most prevalent of which is myeloperoxidase. The peroxidatic metabolism of the benzene metabolites, phenol and hydroquinone, results in arachidonic acid peroxidation and oxygen activation to superoxide radicals, respectively. These metabolites, upon co-administration also produce a myelotoxicity similar to that observed with benzene. Recently, we have found that exposure of human promyelocytic leukemia (HL-60) cells (a cell line rich in myeloperoxidase), to the benzene metabolites, hydroquinone and 1,2,4-benzenetriol results in increased steady-state levels of 8-hydroxydeoxyguanosine a marker of oxidative DNA damage. Peroxidatic metabolism of benzene's phenolic metabolites may therefore be responsible for the increased free radical activity and toxicity produced by benzene in bone marrow. We thus hypothesize that free radicals contribute, at least in part, to the toxic and leukemogenic effects of benzene.

Keywords—Benzene, Free radicals, Lipid peroxidation, Oxidative DNA damage, Genotoxicity, Myelotoxicity, Leukemia

Address all correspondence to Martyn T. Smith Department of Biomedical and Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA 94720.

Vangala Subrahmanyam obtained his Ph.D. in 1986 from Memorial University of Newfoundland, Canada. After two years of postdoctoral studies at the School of Pharmacy, University of Colorado, Boulder, CO, he joined the Department of Biomedical and Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, where he is currently appointed as Assistant Specialist Scientist. David Ross received his Ph.D. in 1982 from the University of Aston at Birmingham in England. After postdoctoral studies at the Department of Forensic Medicine, Karolinska Institute, Stockholm, Sweden, and the School of Public Health, University of California, Berkeley, CA, he moved to the School of Pharmacy, University of Colorado, Boulder, CO, where he is currently Associate Professor of Toxicology. David Eastmond received his Ph.D. in 1987 from the School of Public Health, University of California, Berkeley, CA. He spent two years as a Alexander Hollaender Distinguished Postdoctoral fellow at Lawrence Livermore National Laboratories, CA, and now is an Assistant Professor of Toxicology at the University of California, Riverside. Martyn Smith obtained his Ph.D. from the University of London in 1980, was a postdoctoral fellow at the Karolinska Institute and is now Associate Professor of Toxicology in the school of Public Health, University of California, Berkeley, CA. All investigators have a long-standing interest in oxygen radical and quinone-mediated toxicity and carcinogenicity.

INTRODUCTION

Benzene (BZ) is an ubiquitous environmental pollutant and an important industrial chemical. the annual production of which has been estimated to be over one billion gallons in the U.S. alone. BZ is a constituent of gasoline and is also used in the manufacture of a wide variety of consumer goods such as plastic containers, radios, toys, sporting goods, furniture, appliances, automobiles, tires, adhesives, textiles, dyes, drugs, pesticides, lubricants, solvents and cleaning products. In addition, BZ may be found as a contaminant in drinking water, ambient air, and certain types of foods.¹⁻⁶

Extensive epidemiological studies have linked occupational exposure to BZ with the incidence of bone marrow toxicity and a variety of leukemias in human. However, despite extensive research, the molecular mechanisms responsible for the induction of bone marrow toxicity and leukemia by BZ have yet to be fully elucidated. It is generally accepted that BZ re-

quires metabolism to induce its toxic effects.¹⁰⁻¹⁴ Metabolism of BZ is very complex (Fig. 1) and is not completely understood. Numerous in vivo and in vitro studies have shown that BZ is primarily metabolized to phenol (PH), hydroquinone (HQ), catechol (CAT) and 1,2,4-benzenetriol (BT).¹³⁻³⁰ The majority of these phenolic metabolites are excreted in urine as glucuronide and sulfate conjugates. Some of the HQ and CAT, however, is further metabolized to reactive 1,4-benzoquinone (1,4-BQ) and 1,2-benzoquinone (1,2-BQ), respectively. Some investigators believe that these quinones are responsible for BZ-induced toxic effect.^{1,31} BZ has also been shown to be metabolized to a ring-opened oxidation product, *trans,trans*-muconic acid, which has been detected in both bone marrow and urine after administration of BZ to mice. The corresponding dialdehyde *trans,trans*-muconaldehyde (*t,t*-MA) has also been proposed to be one of BZ's toxic metabolites. Although this aldehyde has not yet been detected in vivo, studies by Lamano *et al.*³² have demonstrated that mouse liver microsomes can metabolize BZ to a product, which co-elutes with *t,t*-MA.

The myelotoxic effects of BZ have also been associated with free radical formation, either as BZ metabolites or oxygen radicals and lipid peroxidation products.³³⁻³⁵ Several reviews of BZ-induced myelotoxic effects in relation to its metabolism have dealt with quinones and/or *t,t*-MA as the ultimate toxic metabolites. Little attention has been paid, however, to the toxicological significance of free radicals as ultimate toxic species. In this review we have attempted to compile the available evidence on free radical formation and associated damage during the oxidation of BZ and its metabolites and discuss their role in BZ-induced myelotoxicity and carcinogenicity.

FREE RADICALS

A free radical has been defined as any molecule that contains an odd number or unpaired electron.³⁶ A free radical is usually depicted as R[•], where the dot represents the unpaired electron. Most free radicals are highly reactive and are short lived. The formation and reactions of free radicals are classified as three steps namely initiation, propagation, and termination. Initiation of free radical formation in biological systems may occur during enzymatic- or auto-oxidation or during reduction. The extent of propagation and termination reactions depends upon the reactivity of the initiated free radical and the environment in which the radical is formed.

The biological threat from free radicals has been thought to be due to their interaction with cellular di-

oxygen. Lipids, thiols, proteins, and DNA.³⁶⁻⁴² The reactions of free radicals with dioxygen may either result in the formation of peroxy radicals or superoxide radical anions (O₂^{•-}). The latter are known to dismutate, either spontaneously or catalyzed by superoxide dismutase (SOD), to hydrogen peroxide (H₂O₂). Furthermore, reaction of H₂O₂ and O₂^{•-} in the presence of iron or other transition metals could result in the formation of hydroxyl radicals (HO[•]). In addition, upon supply of energy, ground state dioxygen may be activated into reactive singlet oxygen (¹O₂) species.

The activated oxygen species HO[•] and ¹O₂ may attack cellular DNA resulting in DNA-strand scission,^{43,44} and hydroxylation of bases.⁴⁵⁻⁴⁷ Such processes have been implicated both in the initiation and promotion phases of carcinogenesis.⁴⁸⁻⁵⁰ In addition, reactions of drug-derived radicals or oxygen radicals with cellular lipids may initiate lipid peroxidation.⁴⁰ Free radicals of all types may interact with cellular macromolecules such as DNA, proteins, and carbohydrates and initiate or promote toxic and carcinogenic processes.

BENZENE-INDUCED FREE RADICAL FORMATION IN VIVO

Administration of BZ has been shown to induce the formation of thiobarbituric acid (TBA)-reactive products (having an absorbance maximum of 535 nm) in liver,³³ plasma,³³ and bone marrow³⁴ of rats, suggesting the formation of malondialdehyde-like products (TBA-MDA adducts: $\epsilon = 1.4 \times 10^5 \text{ M}^{-1} \text{ cm}^{-1}$). The authors of these studies have suggested that BZ induces lipid peroxidation. Lamano and coworkers^{32,51,52} have recently demonstrated that *t,t*-MA, the open-ring oxidation product of BZ also forms an adduct with TBA having an absorbance maximum at 490 nm (TBA-*t,t*-MA adduct: $\epsilon = 7.3 \times 10^4$) with little or no absorbance at 535 nm. It therefore appears unlikely that these TBA-reactants absorbing at 535 nm in rats following BZ administration are due to *t,t*-MA. Since these studies did not record the whole spectrum of TBA-reactants, the formation of *t,t*-MA-TBA adducts, in BZ-exposed animals cannot be excluded. It is surprising, however, although the hplc techniques to separate TBA-*t,t*-MA adducts from TBA-*t,t*-MDA adducts have been available for some time,⁵³ these techniques have not been applied to detect the formation of *t,t*-MA adducts in BZ exposed animals. Nevertheless, Gaido and Wierda⁵³ have shown that BZ administration increases PGE₂ levels in bone marrow indicating increased arachidonic acid peroxidation. Laskin *et al.*⁵⁴ have demonstrated an increase in the phagocytic activity of bone marrow macrophages and granulocytes of Balb/c mice treated with BZ (880 mg/kg) relative to




Fig. 1. Metabolic pathways of benzene (adapted from refs. 13, 14).

the control animals treated with saline or corn oil. They also indicated that a similar increase in phagocytic activity of bone marrow is observed following combined exposure of mice to HQ (50 mg/kg) and PH (50 mg/kg). Khan et al.³⁵ showed that the S-9 fractions isolated from bone marrow of female albino rats following the administration of BZ (0.5 ml/kg), had higher capacity to oxidize dimethyl sulfoxide (a HO' scavenger), to formaldehyde and deoxyribose to thiobarbituric acid-reactive products, indicating that BZ may increase the HO' production in bone marrow. Anwar et al.³⁵ have shown that dimethyl sulfoxide, can indeed reduce the formation of micronuclei in erythrocytes of BZ-exposed mice, presumably by scavenging HO'. These authors, however, suggested that this reduction of BZ-induced genotoxic effects by dimethyl sulfoxide, may be due to the inhibition of HO'-mediated BZ oxidation to genotoxic *t,t*-MA, but mechanism for dimethyl sulfoxide effects remain unclear. Taken together, these studies indicate that administration of BZ to rodents increases the generation of oxygen radicals and lipid peroxidation in bone marrow.

Recently, Ekstrom et al.⁵⁶ demonstrated excretion of malondialdehyde in urine of male Sprague-Dawley rats given HQ (100 or 200 mg/kg) by stomach tube. In a follow-up study, this group demonstrated that HQ administration to these rats also results in the depletion of hepatic glutathione (GSH). These authors suggested that the malondialdehyde excretion in urine that occurs following ingestion of HQ to rats is presumably due to lipid peroxidation that occurs following a depletion of hepatic GSH, similar to that observed in isolated hepatocytes.^{58,59}

The above studies suggest that free radical formation during the metabolism of BZ in bone marrow could play a role in BZ-induced myelotoxicity. Furthermore free radical formation could play a role in the carcinogenicity of HQ to mouse liver.⁶⁰ The following sections present the evidence for free radical formation during the *in vitro* metabolism of BZ and its phenolic metabolites in order to understand the exact mechanisms by which BZ-exposure could lead to the formation of free radicals in bone marrow. We have also reviewed the literature on the mechanisms of interaction of free radical metabolites of BZ with dioxygen and cellular targets such as DNA, GSH, proteins and lipids and the potential significance of such reactions in BZ-induced myelotoxicity and leukemia will be discussed.

FREE RADICAL FORMATION DURING ENZYMATIC METABOLISM OF BENZENE AND ITS METABOLITES *IN VITRO*

Interest in free radical reactions of BZ metabolites stems primarily from the presence of high levels of heme-protein peroxidase enzymes in bone marrow and their ability to oxidize various phenolic compounds to free radicals. Myeloperoxidase (MPO) and eosinophil peroxidase (EPO) enzymes constitute the majority of the peroxidase activity detected in bone marrow.⁶¹ However, some investigators have suggested that the peroxidase activity of prostaglandin (H) synthase (PGS) may also contribute to the bioactivation of phenolic metabolites of BZ in bone marrow.^{53,62-65} This section focuses mainly on MPO- and PGS-catalyzed me-




Fig. 2. Catalytic cycle of horseradish peroxidase (adapted from ref. 66). RH and R• represent electron donor and its free radical product respectively. Phenolic metabolites (phenol, hydroquinone and catechol) of benzene could also serve as electron donors to compounds I and II.^{67,83}

tabolism of phenolic metabolites of BZ. The relative roles of these enzymes in catalyzing the bioactivation of BZ and its metabolites to free radical intermediates is unclear. Studies performed with neutrophils, bone marrow cells, and homogenates and the specific cell types of bone marrow are also described to indicate that peroxidase(s) present in these preparations can catalyze the bioactivation of BZ's phenolic metabolites similar to purified enzymes.

A. Mechanisms of peroxidase-catalyzed oxidations

The mechanisms of peroxidase-catalyzed oxidations of electron donors have been studied by several investigators using horseradish peroxidase (HRP), a model plant peroxidase. Peroxidase enzymes contain an iron-porphyrin complex at the active site that can reduce peroxides^e (Fig. 2). During this process the resting enzyme which contains an Fe³⁺ heme iron is oxidized to compound I, which is believed to contain two oxidizing equivalents above the resting state (Fe⁵⁺).⁶⁷ More recent studies have demonstrated that only one oxidizing equivalent is present in the iron moiety. The other oxidizing equivalent resides on the porphyrin moiety as a porphyrin Π -cation radical.^{68–70} Compound I can be reduced by a variety of electron donors to compound II. Compound II has been shown to be at Fe⁴⁺ oxidation state like compound I, but does not contain the porphyrin Π -cation radical.^{71,72} Compound II can also be reduced by electron donors releasing the native enzyme (Fe³⁺). During the reduction of compound I and compound II by electron donors, highly reactive free-radical metabolites of electron donors can

be formed.⁶⁷ Pioneering work of Yamazaki *et al.*^{73–75} demonstrated that phenolic compounds were excellent electron donors for the higher oxidation states of HRP. BZ, however, is not an electron donor for higher oxidation states of HRP formed from interaction with hydrogen peroxide (Subrahmanyam, V.V., unpublished). Unfortunately, the chemistry of heme-prosthetic group in MPO is not well understood, but recent studies by Dugad *et al.*⁷⁶ indicate that the ¹H NMR spectrum and the nuclear Overhauser effect (NOE) of cyanide-ligated femc complex of MPO (MPO-CN) were remarkably similar to the prosthetic group of lactoperoxidase. Nicholl and coworkers,⁷⁷ showed that the prosthetic group of lactoperoxidase is an iron-porphyrin thiol. Whatever the structure of the heme prosthetic group of MPO is, it forms spectral complexes with H₂O₂^{78–80} similar to that of HRP.⁶⁶ This indicates that MPO is potentially a good candidate in catalyzing the phenolic metabolites of BZ to free radicals.

B. Myeloperoxidase-catalyzed metabolism of the phenolic metabolites of benzene

Using the purified human MPO we studied the metabolism of PH,^{81–83} HQ,^{12,82,83} and CAT^{83,84} to determine the mechanisms of their oxidation by MPO. Our studies show that HQ has the highest specificity for MPO followed by CAT and PH indicating that HQ is a better substrate for MPO than either CAT or PH. PH metabolism by human MPO results in the formation of 2,2'-biphenol and 4,4'-biphenol initially, which are further metabolized rapidly by MPO (Fig. 3). Studies with HRP as a model peroxidase indicate that 2,2'-biphenol is the major metabolite of peroxidase-mediated oxidation of PH.^{85–88} The formation of biphenolic metabolites is indicative of initial phenoxy radical formation, the dimerization of which results in the formation of biphenols. Biphenols are also substrates for peroxidases. Our studies with both MPO and HRP show that further metabolism of 2,2'-biphenol results in the formation of insoluble melanin-like polymers as dark brown colored granular specks.⁸⁹ 4,4'-Biphenol metabolism results in the formation of 4,4'-biphenylquinone, which in the presence of GSH results in the formation of GSH-conjugates.^{81,89}

Catechol metabolism by human MPO and H₂O₂ results in the formation of 1,2-BQ.⁸⁰ Kalyanaraman and associates^{90,91} have shown that CAT metabolism by HRP and H₂O₂ proceeds through initial 1,2-benzosemiquinone radical (1,2-SQ^{••}) formation. The fate of 1,2-SQ^{••} appears to be its spontaneous disproportionation to 1,2-BQ and CAT. Using HPLC analysis, we characterized 1,2-BQ as its bromothiophenol adduct




Fig. 3. Mechanisms of metabolic activation of phenol by human myeloperoxidase (adapted from ref. 12).

during the metabolism of CAT by MPO/H₂O₂ or HRP/H₂O₂.⁸⁰ 1,2-BQ could not be isolated and purified due to its instability. Subsequently, we analysed GSH-conjugates formed during CAT metabolism by MPO/H₂O₂ or HRP/H₂O₂ in the presence of GSH. Two GSH-conjugates were formed, the major conjugate appears to be the mono GSH-conjugate of 1,2-BQ (Fig. 4). The fate of GSH-conjugates of CAT, if formed in bone marrow, is unclear.

Hydroquinone metabolism by human MPO and H₂O₂ results in the formation of 1,4-BQ as the major metabolite.⁷⁷ Yamazaki and coworkers⁷³⁻⁷⁵ have demonstrated that the oxidation of HQ by HRP and H₂O₂ proceeds through 1,4-benzosemiquinone radical (1,4-SQ^{•-}) intermediate. The fate of 1,4-SQ^{•-} appears to

be its spontaneous disproportionation to 1,4-BQ and HQ, similar to that of 1,2-SQ^{•-}. However, 1,4-SQ^{•-} may, under certain conditions, also react with dioxygen resulting in the generation of O₂^{•-}, which will be discussed later in this article.

C. Metabolism of benzene and its phenolic metabolites by neutrophils

Neutrophils typically make up 50–70% of the white cell fraction of human peripheral blood.⁹² Large numbers of immature neutrophils also reside in the BM.⁹³⁻⁹⁶ MPO comprises 5% of the dry weight of neutrophils.⁹⁷ Neutrophils also possess the ability to be stimulated by several particulate and nonparticulate agents resulting in oxygen radical generation.⁹⁸ This process, known as the "oxidative burst" is due to the activation of a membrane-bound NADPH oxidase which is dormant in resting cells and becomes activated during phagocytosis or following interaction with suitable stimulants. Flavoproteins, cytochrome b₅₅₈ and ubiquinone have been proposed to be the components of this oxidase-system. The presence of ubiquinone is, however, controversial. Many of the stimulants of the oxygen radical activity in neutrophils appears to mediate their actions by activating protein kinase C, either by a direct interaction or indirectly by receptor-triggered cascade (Fig. 5).⁹⁷ The receptor-triggered cascade involves the activation of phospholipase C, which acts on phosphatidyl inositol (P-inositol) and hydrolyses it to diacylglycerol. The compounds having structural similarity to diacylglycerol, such as phorbol myristate acetate (PMA; stimulant 4, Fig. 5) have been shown to directly activate protein kinase C.⁹⁹ protein kinase C appears to regu-




Fig. 4. Mechanisms of metabolic activation of catechol by human myeloperoxidase.




Fig. 5. pathways for stimulation of NADPH-oxidase activity (adapted from ref. 98). Benzene may also stimulate NADPH oxidase activity through protein kinase C activation.^{100,101}

late the activity of NADPH oxidase and result in the stimulation of oxidative burst in neutrophils. Recent studies by Castagna and colleagues^{100,101} have shown that BZ can activate protein kinase C activity in intact platelets isolated from rabbit blood, but very high concentrations of BZ (0.8 - 4.8%) are required. The physiological relevance of this phenomenon is doubtful.

PMA is known to activate protein kinase C in human promyelocytic leukemia (HL-60) cells and also results in the differentiation of these cells to macrophages.¹⁰²⁻¹⁰⁶ HL-60 cells, however, do not possess oxidative burst, but do develop the oxidative burst during their differentiation to macrophages.¹⁰³ Recent studies by Kalf and colleagues have shown that incubation of HL-60 cells with BZ induces differentiation of these cells into macrophages,¹⁰⁷ presumably by activating protein kinase C. In contrast, pre-incubation of HL-60 cells with HQ (0.5 - 5 μ M) inhibits the PMA-induced differentiation of HL-60 cells¹⁰⁸ suggesting that HQ or its metabolite 1,4-BQ may act by inhibiting protein kinase C. It is interesting to note that BZ and its metab-

olite HQ have contrasting effects on HL-60 cell differentiation. The relevance of these studies in BZ-induced myelotoxic effects is not clear.

Kalir *et al.*¹⁰⁹ have shown that addition of high concentrations of BZ (1.3 mM) to human neutrophils results in a marked decrease in the number of cellular granules, a decrease in the amount of heterochromatin and a rarefaction (decreased density) of ribosomes. These effects of BZ were prevented in the incubations containing 2-aminoethylthiosulfuric acid, a free radical scavenger. These authors concluded a free radical metabolite of BZ was responsible for the observed toxic effects on neutrophils, but did not determine the nature of the free radical metabolite.

We have shown that PH and HQ are activated to DNA and protein-binding metabolites by intact neutrophils stimulated with the tumor promoter PMA.¹¹⁰⁻¹¹² Inhibitors of MPO such as azide and cyanide inhibited the PH¹¹² and HQ¹¹¹ induced DNA- and protein-binding, respectively, in neutrophils, indicating that MPO is involved in the activation of these phenolics in neutrophils. SOD, which increases the dismutation of

$O_2^{\cdot-}$ to H_2O_2 , increased the covalent binding of PH to neutrophil DNA. Conversely, catalase, which decomposes H_2O_2 to dioxygen and water, decreased the covalent binding of PH to neutrophil DNA.¹⁰⁰ These results indicated that H_2O_2 is required for the activation of PH and HQ to products that covalently bind to neutrophil DNA and protein.

Since H_2O_2 is required for peroxidatic metabolism of BZ's phenolic metabolites, we have attempted to determine whether they activate neutrophil NADPH-oxidase activity similar to PMA and thus generate H_2O_2 required for their metabolism by MPO. Our efforts using manometric studies (Subrahmanyam, V.V. and O'Brien, P.J., unpublished) and cytochrome c reduction (Eastmond, D.A. and Smith, M.T., unpublished), to determine whether the phenolic metabolites of BZ could stimulate the oxidative burst in neutrophils were negative but inconclusive. It is possible that these techniques are not sufficiently sensitive to detect small increases in oxidative burst activity in neutrophils. Alternatively, it is possible that BZ and its metabolites could prime the NADPH oxidase activity for activation by endogenous stimulants. In support of this, Laskin et al.¹⁰¹ have recently demonstrated an increase in phagocytic activity of bone marrow cells of mice administered with BZ or PH and HQ, indicating that BZ or phenolic metabolites of BZ may act by priming the NADPH-oxidase activity of bone marrow cells. Unfortunately, whether such priming of NADPH oxidase activity, by BZ or its phenolic metabolites, occurs in vitro and neutrophils or bone marrow cells has not been tested.

D. Metabolism of benzene and its phenolic metabolites by bone marrow cells and homogenates

Benzene metabolism in bone marrow homogenates is mediated by the cytochrome P450 monooxygenase system.¹¹³⁻¹¹⁵ This enzyme system has been shown to hydroxylate BZ to PH. The significance of cytochrome P450, however, in the hydroxylation of BZ in situ in bone marrow is not clear and requires further work. The mechanism(s) of BZ hydroxylation to PH has been reviewed extensively in the recent years and therefore we suggest that interested readers consult those reviews.^{10,11}

We have shown that bone marrow cells and homogenates of rat, mouse, and human have the capacity to metabolize PH.^{95,116} HQ⁹⁵ and CAT¹¹⁷ in the presence of H_2O_2 as cofactor. In mouse bone marrow cells binding of ^{14}C -CAT metabolites to protein (20 nmol/mg protein) was found to be twice that obtained with ^{14}C -HQ (10 nmol/mg protein) and twelve-fold higher than that obtained with ^{14}C -PH (1.5 nmol/mg protein).⁹⁵




Fig. 6. Arachidonic acid metabolism by prostaglandin H synthase. RN and R[•] represent electron donor and its free radical product, respectively. Phenolic metabolites (phenol, hydroquinone, and catechol) of benzene could also serve as electron donors for the peroxidase activity of prostaglandin H synthase.^{64,65}

Metabolism of PH by rat bone marrow homogenate in the presence of H_2O_2 has been shown to result in the formation of 2,2'- and 4,4'-biphenol as the major metabolites¹¹⁶ indicating the peroxidative nature of the metabolism. Extensive protein binding of PH-equivalents to bone marrow homogenate also occurred. Using HRP and hydrogen peroxide as a model system, we have characterized the nature of products binding to bovine serum albumin. This protein-binding appears to result from a noncovalent interaction of polymers (further oxidation products of 2,2'-biphenol) as well as a covalent interaction of 4,4'-diphenylquinone (further oxidation product of 4,4'-biphenol) with sulfhydryl groups of albumin). The binding of the polymers to protein is so strong that normal procedures for establishing covalent binding to protein were not effective in removing all of these polymers from protein. Enzymic digestion of protein, however, resulted in the release of the polymers from protein. A charge-transfer complex formation between the polymers and the protein has been tentatively suggested as an explanation for this noncovalent, yet strong interaction of these polymers with protein. The toxicological significance of this type of interaction is not clear, but such an ex-

tensive protein-binding could result in the inactivation of various cellular enzymes and contribute to cytotoxic events. Extensive noncovalent binding of polymeric oxidation products of PH with DNA has also been observed during a peroxidatic metabolism, which will be described in later sections.

Metabolism of CAT by rat and human bone marrow cells also results in the formation of reactive metabolites that bind to protein.¹¹⁷ Protein binding could be inhibited by GSH. We have shown that the GSH-conjugates are formed from the reaction of GSH with 1,2-BQ formed during the metabolism of CAT. Although H₂O₂-dependent metabolism of HQ and CAT in bone marrow could be catalyzed by either peroxidases or cytochrome P-450, indirect evidence using inhibitors suggest that cytochrome P-450 plays little role in peroxidatic bioactivation in bone marrow.¹¹⁷

E. Metabolism of phenolic metabolites of benzene by specific cell types of bone marrow

Bone marrow stroma primarily consists of two cell types (macrophages and fibroblastoid stromal cells) which appear to control the differentiation and maturation of myelopoietic cells via the production of growth factors.¹¹⁶ Studies from Wierda's¹¹⁹ laboratory have shown that macrophages are more sensitive than fibroblastoid stromal cells to the toxic effects of HQ. Interestingly, bone marrow macrophages contain appreciable peroxidase activity while fibroblastoid cells do not.¹²⁰ Hydrogen peroxide-dependent bioactivation of HQ occurred readily in bone marrow macrophages, but not in fibroblastoid stromal cells, indicating macrophages contain an active peroxidase.

The selective toxicity of HQ to bone marrow macrophages rather than fibroblastoid stromal cells could be a result of both increased peroxidative activation of HQ to 1,4-BQ in the macrophage and an increased deactivation of 1,4-BQ in the fibroblast by the obligate two electron reductase, DT-diaphorase.¹²¹ Inhibition of DT-diaphorase by dicumarol in the stromal fibroblast, but not in the stromal macrophage, has been shown to lead to increased covalent binding of HQ to protein.¹²¹ These data and previous work,¹²² suggest that activation and deactivation mechanisms, such as peroxidase and DT-diaphorase, respectively, in individual cell types are an important determinant of the cell specific toxicity of phenolic metabolites of BZ.

F. Prostaglandin (H) synthase-catalyzed metabolism of phenolic metabolites of benzene

Prostaglandin (H) synthase (PGS), another heme-protein enzyme that is mainly involved in arachidonic

acid (AA) metabolism to generate prostaglandins, has also been implicated in cooxidation of several carcinogens and drugs to reactive species (Fig. 6).^{123,124} This enzyme has two distinct activities, being both a cyclooxygenase and a peroxidase. It has been established that AA is oxygenated by the cyclooxygenase activity of this enzyme to generate the endoperoxy hydroperoxide (PGG₂). Two molecules of oxygen are incorporated into AA during this process. This hydroperoxide is subsequently reduced to a hydroxy derivative of AA (PGH₂) by the peroxidase activity of PGS. This peroxidase activity of PGS is similar to the peroxidase activity of other peroxidases and cooxidizes a wide variety of electron donors to free radical intermediates.^{123,124} Indomethacin, a nonsteroidal anti-inflammatory drug has been shown to inhibit the cyclooxygenase activity of PGS but has no effect on its peroxidase activity.¹²⁵ Prostaglandins, such as PGE₂, have been shown to down-regulate granulocyte/monocyte colony formation and may contribute to the myelotoxic effects of BZ. Wierda and his associates⁵³ have demonstrated that intraperitoneal administration of BZ (200 mg/kg; twice a day for four days) to male B6C3F₁ mice elevates PGE₂ levels in bone marrow. This increase was prevented by pretreatment of mice with indomethacin (2 mg/kg). Further studies by Kalf *et al.*^{62,63} have demonstrated that indomethacin (2 mg/kg) can alleviate the genotoxic effects (micronucleus formation)⁶² and bone marrow depression⁶³ induced in bone marrow following intraperitoneal administration of BZ (0–1200 mg/kg twice daily for two days) to Swiss–Webster male mice. These results led Kalf *et al.*^{62,63} to suggest that PGS activity in bone marrow may be involved in the myelotoxic effects of BZ.

The major problem with this hypothesis is that indomethacin is assumed to be a specific inhibitor of PGS and to act only in the bone marrow. Indomethacin may have profound effects on the toxicokinetics of BZ and its metabolites. It can also inhibit MPO,¹² BZ-dihydrodiol dehydrogenase¹²⁶ and diglyceride lipase.¹²⁷ and ingestion of indomethacin (5 mg/kg) has also been shown to reduce intestinal peroxidase activity in rats.^{128,129} Moreover, PGS has never been purified from bone marrow. To date there are only two major peroxidases isolated from bone marrow, i.e., MPO and EPO.⁶¹ Recently, Zilletti *et al.*¹³⁰ have shown that HRP and bovine milk lactoperoxidase are capable of oxidizing AA to prostaglandins, but this activity has yet not been demonstrated with either MPO or EPO. However, they did show that indomethacin inhibited the peroxidase-dependent formation of PGE₂ from AA with an IC₅₀ of 3 μ M. Thus, it is possible, that the prostaglandins detected in bone marrow after BZ administration are the result of peroxidase activity and not that of PGS.

Early studies by Christ and Van Dorp¹³¹ indicated that guinea pig bone marrow contains no detectable **PGS** activity. Ziboh et al.¹³² incubated bone marrow microsomes (isolated from Sprague-Dawley rats) with ¹⁴C-AA and found that PGE₂ and PGF₂ (another prostaglandin metabolite of AA) were the major metabolites. These studies contained at least 6-mg microsomal protein in 2 ml of reaction mixture. The total conversion of AA into the products was found to be less than 2%. These incubations also contained HQ (0.55 mM), presumably to prevent the rapid inactivation of cyclooxygenase activity by AA metabolites. However, no studies were performed by these authors to determine the fate of added HQ. Kojima et al.¹³³ incubated ¹⁴C-AA with 15 mg of whole bone marrow homogenate (prepared from male Wistar rats) in 0.5 ml of incubation mixture and found that approximately 80% of the added AA was converted into three products. The major product, which contained approximately 60% of the incubated AA, was not identified and was assumed to be a nonprostaglandin derivative due to its distinct chromatographic properties. The other major product, which contained approximately 20% of the incubated AA, was tentatively identified as prostaglandin D₂. Formation of these metabolites from AA is completely inhibited by indomethacin (25 μM).

The requirement of large amounts of bone marrow protein to study the metabolism of AA by bone marrow suggests that bone marrow contains very low levels of prostaglandin biosynthetic capability. Ziboh et al.¹³² reported that microsomes isolated from hyperplastic bone marrow (turpentine-induced) contained 2.5-fold higher prostaglandin biosynthetic activity compared to the activity in normal bone marrow microsomes. However, the total formation of PGE₂ and PGF₂ in hyperplastic bone marrow represented only 4.2% of incubated AA.

Gaido and Wierda⁵³ suggested that macrophages present in adherent bone marrow stromal cells could be the source of **PGS** activity in bone marrow. These authors found that incubation of HQ with adherent bone marrow stromal cell cultures induced PGE₂ synthesis in these cells. They also showed that the stromal cells incubated with HQ also prevented granulocyte/monocyte colony formation in co-culture. The presence of indomethacin in these incubations ameliorated the toxic effects of HQ on granulocyte/monocyte colony formation. Interestingly, indomethacin was not able to reduce the PGE₂ levels induced by HQ in these cultures. These authors concluded that HQ-induced stromal cell toxicity was not solely due to increased **PGS** activity.

Kalf et al.⁶²⁻⁶⁵ however, maintain that bioactivation of phenolic metabolites of BZ by **PGS** is an important step in BZ-induced bone marrow myelotoxicity. These authors conducted a series of experiments using purified

PGS (from ram seminal vesicles) and isolated peritoneal macrophages (from the peritoneal cavity of male C57BL/6 mice).^{64,65} Their experiments showed that purified **PGS**, either in the presence of AA or H₂O₂, readily catalyzes the bioactivation of ¹⁴C-PH and ¹⁴C-HQ to reactive protein-binding metabolites. These authors also showed that a similar H₂O₂-dependent bioactivation of HQ and PH occurs in peritoneal macrophages, indicating a peroxidase is responsible. The observation that purified **PGS** can catalyze activation of phenolics via cooxidative mechanisms is not surprising, and the critical question is the role of **PGS** in bioactivation of phenolics in bone marrow cells in general and macrophages in particular. Using white bone marrow cell fractions from either mouse (Ross, D., unpublished) or rat¹¹⁷ we have not been able to demonstrate a major role for **PGS** in bioactivation of phenolics to protein binding species. Studies in purified bone marrow cell types are of more relevance, however, and using bone marrow macrophages, rather than peritoneal macrophages, we have shown that they are indeed capable of peroxidatic bioactivation of HQ to 1,4-BQ, which can either form a GSH-conjugate and/or covalently bind to protein.¹²⁰ We have been unable to demonstrate arachidonate stimulated covalent binding of ¹⁴C-HQ to protein, which would implicate **PGS** in the binding process, in bone marrow macrophages (Ganaosis, L. and Ross, D., unpublished). Schlosser and Kalf,^{64,65} however, have reported such a stimulation, albeit marginal, in peritoneal macrophages. Michel et al.¹³⁴ found that mouse bone marrow macrophages can catalyze the synthesis of PGD₂ from AA that is associated with endogenous peroxidase activity. The nature of peroxidase present in the bone marrow macrophages may therefore be **MPO** or an, as yet, uncharacterized peroxidase. Since peroxidases other than **PGS** have also been shown to transform AA to prostaglandins, it remains to be determined whether the prostaglandin biosynthetic activity of bone marrow macrophages is due to **PGS** or other peroxidases.

Clearly much more work needs to be done to determine whether **PGS** plays a role in modulating BZ toxicity. Whether the role, if any, of **PGS** in BZ toxicity is at the level of peroxidatic activation of phenolic metabolites to reactive species or is a result of altered levels of eicosanoids in bone marrow due to the presence of BZ metabolites remains to be determined.

MOLECULAR AND CELLULAR EFFECTS OF BENZENE AND ITS METABOLITES

In order to understand the mechanisms by which BZ exerts its toxic and leukemogenic effects, numerous studies have attempted to identify the cellular and mo-

Table 1. A Comparison of HRP/H₂O₂-Mediated Binding of Oxidation Products of ¹⁴C-phenol, ¹⁴C-catechol and ¹⁴C-hydroquinone to Calf Thymus DNA

Condition ^a	¹⁴ C-bound to DNA (nmol/mg)
Phosphate Buffer (0.1 M, pH 7.4)	
¹⁴ C-PH, HRP, H ₂ O ₂ , DNA	66.8 ± 15.7 ^b
minus HRP	0.6 ± 0.2
¹⁴ C-CAT, HRP, H ₂ O ₂ , DNA	14.6 ± 1.2
minus HRP	0.5 ± 0.2
¹⁴ C-HQ, HRP, H ₂ O ₂ , DNA	0.56 ± 0.18
minus HRP	0.46 ± 0.2
Tris HCl Buffer (0.1 M; pH 7.4)	
¹⁴ C-PH, HRP, H ₂ O ₂ , DNA	42.1 ± 8.4
minus HRP	0.6 ± 0.1
¹⁴ C-CAT, HRP, H ₂ O ₂ , DNA	4.89 ± 0.12
minus HRP	0.38 ± 0.04
¹⁴ C-HQ, HRP, H ₂ O ₂ , DNA	0.33 ± 0.08
minus HRP	0.24 ± 0.05

^aIncubations of either phosphate or tris-HCl buffer, contained phenolic substrate (200 μM), HRP (10 μg) DNA (1 mg). The reactions were initiated with the addition of H₂O₂ (400 μM) and incubated for 30 min at room temperature. DNA was purified as described previously by Subrahmanyam and O'Brien.^{87,88}

^bValues represent mean ± S.E.M. (n = 3).

molecular effects that occur following exposure to BZ and its metabolites. Most research has focused on the effects of 1,4-BQ and BZ's phenolic metabolites due to evidence for their involvement in myelotoxicity, their commercial availability and their stability in aqueous solutions. Exposure to other reactive BZ metabolites such as 1,2-BQ, *t,t*-MA, or BZ-epoxide may induce similar effects although much less data is available on the adverse effects produced by these compounds. Indeed, Witz *et al.*¹³⁵ have shown that *t,t*-MA is a potent myelotoxicant in CD-1 male mice. The adverse effects of the benzoquinones and *t,t*-MA are primarily related to their ability to react with nucleophilic sulfhydryl and amino groups at key functional sites on proteins and with nucleophilic sites on DNA. In addition, the ability of quinones to undergo cyclic reduction and oxidation reactions (redox cycling), producing oxygen- and lipid-derived radicals, has also been implicated in the induction of pathological effects by these compounds. The following sections will overview the research efforts in five areas, DNA damage, protein damage, oxygen activation, GSH oxidation and lipid peroxidation, which have been proposed as being involved in the hematotoxic effects of BZ.

A. DNA-damage

Due to an association between neoplastic development and the ability of many chemical carcinogens to bind to DNA,¹³⁶ considerable research has focused on the interaction of BZ and its metabolites with DNA.

Initial studies by Lutz and Schlatter¹³⁷ recovered radioactivity bound to rat liver DNA following the administration of tritiated and ¹⁴C-BZ to male rats. Additional studies by Gill and Ahmed¹³⁸ and Arfellini *et al.*¹³⁹ demonstrated that BZ (or metabolites) was capable of binding to bone marrow DNA following in vivo administration. More recently, a series of investigations has focused on the ability of the individual BZ metabolites to bind to deoxynucleotides and DNA in vitro.¹⁴⁰⁻¹⁴⁵ These studies have indicated that 1,4-BQ, HQ, PH, BT, *t,t*-MA, and CAT are all capable of forming adducts with deoxynucleotides and DNA during in vitro incubations. However, the nature of the binding in the bone marrow and the identity of the reactive species involved remain largely unknown.

We have performed extensive in vitro studies to determine whether free radicals or other oxidation products of BZ could bind to the DNA. Table 1 shows a comparison of binding of reactive metabolites of ¹⁴C-PH, ¹⁴C-CAT, and ¹⁴C-HQ formed during a peroxidase-catalyzed reaction. The reactions were performed in phosphate buffer as well as in tris-HCl buffer at pH 7.4. Extensive binding of PH and CAT oxidation products to DNA was observed. The binding of ¹⁴C-PH, or "C-CAT oxidation products to DNA is better in phosphate buffer than in tris-HCl buffer. Oxidation of "C-HQ, either in phosphate buffer or in ms-HCl-buffer, however, resulted in no significant increase in the binding of ¹⁴C-HQ oxidation products to DNA compared to that in the absence of enzyme. Nonenzymic binding to DNA, of HQ-autooxidation products, is also not significantly different in both buffers. Previous studies aimed at determining the ability of 1,4-BQ to bind DNA and RNA, during microsomal activation of ¹⁴C-BZ or "C-PH, have resulted in contradictory results. The studies by Subrahmanyam and O'Brien⁸⁸ and Tunek *et al.*'s²⁹ failed to detect any covalent binding of ¹⁴C-PH oxidation products with DNA or RNA, during microsome-mediated activation although PH metabolism occurred. Arfellini *et al.*,¹³⁹ however, found a significant association of radioactivity with DNA during microsomal activation of ¹⁴C-BZ, which was attributed to a covalent interaction of 1,4-BQ with DNA. In addition, Snyder and coworkers^{141,142} found that 1,4-BQ covalently interacts with DNA following their incubation together. While our studies were performed in tris-HCl buffer,⁸⁸ Arfellini,¹³⁹ and Snyder^{141,142} groups performed their studies in phosphate buffer. The data presented in Table 1, however, shows that there is no significant difference in the DNA-binding of ¹⁴C-HQ oxidation products, in either buffer. Therefore, it is clear that the differences in our results with the other groups were not due to the different buffers used. Nevertheless, the data in Table I indicated that some oxidation products of ¹⁴C-HQ are capable of binding

to DNA, presumably due to autooxidation, since the peroxidatic metabolism of ^{14}C -HQ did not increase this binding that occurred in the absence of the enzyme. On the other hand, the reason for the increased binding of ^{14}C -PH or ^{14}C -CAT oxidation products in phosphate buffer is not clear and remains to be determined. However, an analysis of the DNA-binding of PH oxidation products revealed that most of the binding is due to a noncovalent, charge-transfer complex formation between the melanin-like polymers and DNA.⁸⁷ DNA had no effect on the formation of biphenols which indicated that phenoxy radicals were not capable of binding to DNA. HRP-catalyzed oxidation of CAT also resulted in the formation of black melanin-like products, the formation of which was not inhibited by the presence of DNA (Howell, M.; Ross, D., and Subrahmanyam, V.V., unpublished). Similarly, the peroxidatic metabolism of the bladder carcinogens benzidine,¹¹¹ phenylenediamine¹⁴⁶ and methylaminoazobenzene,¹⁴⁶ and the uterine carcinogen diethylstilbestrol¹⁴⁷ have been shown to form polymeric oxidation products that interact noncovalently with DNA. Peroxidatic metabolism of acetaminophen has also shown to result in the formation of polymers,¹⁴⁸ but whether these products bind to DNA has not been investigated. The interactions of polymers with DNA may result in irreparable mutagenic changes, but this remains to be established. But, if this type of binding occurs in the cells, repair may be difficult and the cell may die readily. Cell proliferation may be initiated in neighbouring less damaged cells.

Snyder and coworkers^{141,142} have isolated DNA adducts formed following chemical oxidation of HQ using FeCl_3 in the presence of DNA or following the incubation of 1,4-BQ with DNA and have identified these adducts as (3'OH) benzethenol(1,N²)deoxyguanosine. These investigators have recently reported, using a ^{32}P -postlabelling technique, formation of several DNA adducts in the liver DNA of rabbits following the in vivo administration of BZ.¹⁴⁹ However, neither the chemical structure of this adduct nor its ability to co-chromatograph with the known standard 1,4-BQ-adducts was determined. In contrast, Reddy and associates,^{150,151} using a nuclease P_1 -enhanced ^{32}P -post-labelling technique, have been unable to detect DNA adducts in the liver, kidney, bone marrow, and mammary gland of rats treated with BZ or PH and HQ. Some preliminary evidence of the formation of adducts in the Zymbal gland of BZ-treated rats was observed during these experiments.

Studies by Norpoth *et al.*¹⁵² have identified N⁷-phenylguanine in the urine of rats following the intraperitoneal administration of BZ at 330–400 mg/kg. These authors suggested that this adduct was formed through the reaction of BZ-epoxide with guanine residues in

DNA and that its presence in the urine was the result of the excision repair of this DNA adduct.

In spite of the considerable effort which has been made to identify DNA binding following BZ administration and to characterize the nature of the DNA adducts, there is no direct evidence for the involvement of these events in BZ-induced leukemia. The degree of covalent DNA binding recovered following BZ administration is low and rankings of carcinogenic agents by DNA binding generally rank BZ among the weakest initiating agents, approaching agents that act through indirect genotoxic mechanisms.^{136,139} Subrahmanyam and O'Brien,⁸⁷ several years ago, found that an in vitro peroxidative metabolism of PH leads to the formation of polymeric products that strongly bind to DNA but do not form covalent adducts. The binding of these polymers to DNA is so strong that normal procedures for establishing covalent binding to DNA were not effective in removing all of these polymers from DNA. Therefore, a strong association of some radioactivity with DNA, following administration of radio-labelled BZ to animals, should not be taken as indicating covalent interaction of BZ metabolites with DNA. In addition, BZ and its metabolites are weakly or nonmutagenic in specific gene mutation assays.¹⁵³ These observations suggest that other types of molecular events are likely to be involved in the development of leukemia by BZ.

B. Protein-damage


One consistent observation that has been made in BZ-exposed humans and animals is the appearance of structural and numerical chromosomal aberrations and sister chromatid exchanges in lymphocytes and bone marrow cells indicating that BZ is genotoxic.^{153–157} Chromosome and chromatid deletions, gaps, chromatid exchanges, hyperdiploidy and micronuclei induction, all have been detected to some extent. Since the induction of chromosomal aberrations in humans have been associated with a variety of neoplastic development,^{158,159} these chromosomal aberrations could also contribute to the myelotoxic and leukemogenic effects of BZ in humans. BZ administration to animals is also accompanied with an inhibition of DNA, RNA, and protein synthesis (reviewed^{10,11}). BZ metabolites interfere with DNA replication and transcription in rat liver and BM mitochondria in vitro that has been attributed to the inhibition of DNA polymerase gamma activity by HQ and 1,4-BQ. Studies by Lee and coworkers¹⁶⁰ have confirmed that an inhibition of DNA synthesis occurs in bone marrow following the in vivo administration of BZ to mice and have indicated that inhibition occurred at doses that had no inhibitory effect on the synthesis of protein or heme. These authors reported that BZ itself had the ability to inhibit DNA synthesis in vitro in

cell-free incubations following the addition of BZ. Additional studies by these investigators studying the effects of individual BZ metabolites indicated that CAT, BT, HQ, and 1,4-BQ were able to inhibit nuclear DNA synthesis in cultured mouse bone marrow cells.¹⁶¹ However, only 1,4-BQ and BT were able to inhibit DNA synthesis in a cell-free system. This effect appeared to be due to an interaction of these compounds with DNA polymerase- α .

The inhibition of DNA polymerase- α or - γ activity by HQ and 1,4-BQ was suggested to be due to the arylation of 1,4-BQ with a critical sulfhydryl group on these proteins.^{10,11,161} Due to the arylating activity of quinones with sulfhydryl groups, Irons³¹ several years ago postulated that quinone metabolites of BZ may act as spindle poisons during cell division and disrupt microtubule assembly. This may cause lagging chromosomes and result in numerical chromosomal aberrations (aneuploidy). Indeed, Irons and colleagues¹⁶² have demonstrated that administration of BZ to animals results in the block of cell division in the G₂ or M phase of the cell cycle, supporting a role for disruption of microtubule assembly. These investigators also found that HQ and 1,4-BQ are highly effective inhibitors of microtubule assembly in mouse lymphocytes¹⁶³ and isolated microtubule preparations.¹⁶⁴ The mechanism of this inhibition appeared to involve the 1,4-BQ-dependent arylation of extremely nucleophilic sulfhydryl groups on tubulin, which function in GTP binding and serve as a control site for the regulation of microtubule assembly. The inhibition of microtubule assembly by 1,4-BQ appeared to parallel the inhibition of cell growth and microtubule assembly induced by the T suppressor cell lymphokine, soluble immune response suppressor (SIRS) suggesting that 1,4-BQ may act by mimicking this intracellular messenger *in vivo*.¹⁶⁰ Although the spindle-poisoning effects by BZ metabolites appears to be a likely mechanism for the induction of numerical chromosomal aberrations, it cannot explain the induction of structural chromosomal aberrations that have been observed following BZ exposure. Such events probably occur via DNA damage, either through oxidative mechanisms or adduct formation.


C. Active oxygen formation

Ground state dioxygen itself is a radical species since it has two unpaired electrons with the same spin number (i.e., mplet state). Supply of energy can activate the triplet oxygen to highly reactive singlet oxygen in which the two-electrons have opposite signs. Other active oxygen species such as O₂^{•-}, H₂O₂, and HO[•] can also be generated during successive one-electron reduction of dioxygen to water [eqn (1)].^{46,50}





Oxygen radicals may attack cellular DNA resulting in DNA-strand scission^{43,44} and base damage.^{45-47,165} Some of the basedamaged products are hydroxylated bases which include 8-hydroxydeoxyguanosine (8-OHdG), thymine glycol (5,6-dihydroxydihydrothymine) and hydroxymethyluracil. Presence of 8-OHdG in DNA has been recently shown to cause DNA-polymerase to miscode nucleotide incorporation in the replicated strand and result in mutagenesis.^{166,167}

Some xenobiotic free radicals have the ability to interact with dioxygen, resulting in O₂^{•-} formation.¹⁶⁸ However, oxidation of PH, CAT, or HQ by peroxidase and H₂O₂, which results in the formation of phenoxyl- or 1,2-SQ^{•-} or 1,4-SQ^{•-} radicals, respectively, did not result in any oxygen consumption.¹⁶⁷ This indicates that these radicals may not be reactive enough to interact with dioxygen. Sawada *et al.*¹⁷⁰ have, however, demonstrated increased 1,4-BQ formation during peroxidase-catalyzed oxidation of HQ in the presence of SOD. They suggested that the reaction of 1,4-SQ^{•-} with dioxygen could indeed occur if the O₂^{•-} are removed from the reaction. This appears to be due to faster back reaction, i.e., reaction of 1,4-BQ and O₂^{•-} forming 1,4-SQ^{•-} and dioxygen [eqn (2)]



Our studies^W confirmed Sawada *et al.*'s¹⁷⁰ study showing an increased production of 1,4-BQ during peroxidatic metabolism of HQ in the presence of SOD. Interestingly, we found no increased production of 1,2-BQ during peroxidatic metabolism of CAT in the presence of SOD.⁸⁴

It has been shown, however, by Kasai and Nishimura¹⁷¹ that incubation of either HQ or CAT with H₂O₂, femc iron (Fe⁺³) and deoxyguanosine results in the formation of 8-OHdG, presumably due to the addition of HO[•] to deoxyguanosine. Recently, Iwahashi *et al.*¹⁷² showed that a variety of catechols, including CAT in the presence of femc iron, EDTA and H₂O₂, could result in the formation of HO[•]. The mechanism appears to be due to the initial reduction of iron from the femc (Fe⁺³) state to ferrous (Fe⁺²) state by CAT. The reaction of Fe⁺² with H₂O₂ thus generates the reactive HO[•] as shown below:



Similarly, HO[•] formation was described by Rao and





Fig. 7. Formation of 8-hydroxydeoxyguanosine in DNA of human promyelocytic leukemia cells exposed to benzene metabolites.

Pandya,¹⁷³ who showed that incubation of HQ or BT with DNA in the presence of copper ions (Cu^{+2}) results in the formation of thiobarbituric acid reactive products. This process was inhibited to some extent by mannitol, a $\text{HO}^\bullet$ scavenger, and also by catalase and SOD, which prevent the $\text{HO}^\bullet$ formation by decomposing H_2O_2 and removing $\text{O}_2^{\bullet-}$, respectively. In contrast, Kawanishi et al.¹⁷⁴ did not detect $\text{HO}^\bullet$ formation using electron spin resonance during auto-oxidation of BT in the presence of copper ions, although they detected $\text{HO}^\bullet$ formation in the presence of iron (Fe^{+3}). They indicated that the DNA-damage induced by BT and copper ions in their studies may not be due to $\text{HO}^\bullet$. Lewis et al.¹⁷⁵ have shown that DNA-damage also occurred during the auto-oxidation of HQ and BT at physiological pH but only the damage induced by the latter was inhibited by scavengers of $\text{O}_2^{\bullet-}$, H_2O_2 , and $\text{HO}^\bullet$. It is likely that the differences in these studies are due to differences in the concentrations employed. The relevance of metal-catalyzed oxygen radical production by BZ metabolites in myelotoxicity induced by BZ is not known, but, it is worth emphasizing that iron accumulation in bone marrow has been observed following administration of BZ to rats.^{34,176} This iron accumulation may be due to the induction of heme oxygenase,¹⁷⁷ which also occurs in rats exposed to BZ. Heme oxygenase is an enzyme responsible for heme degradation to biliverdin.^{178,179} Biliverdin can be further reduced to bilirubin by biliverdin reductase. Iron may be released from heme during its degradation. It is also interesting to note that biliverdin and bilirubin are considered to be good antioxidants.¹⁷⁸ Therefore, it is difficult at this point to emphasize whether induction of heme oxygenase by BZ in bone marrow increases myelotoxicity by releasing iron from heme or prevents the free radical reactions in bone marrow by increasing

the levels of the antioxidants, biliverdin, and bilirubin.


Pellack-Walker et al.¹⁸⁰ have shown that HQ, BT, CAT, and PH are cytotoxic to L5178YS cells, inhibit DNA synthesis and induce DNA-strand breaks in these cells. The inhibition of DNA synthesis by these BZ metabolites correlated inversely with their respective one-electron redox potentials: HQ is most potent followed by BT, CAT, and PH. These authors suggested that oxygen radicals play a major role in the cytotoxicity and DNA strand breaks induced by these BZ metabolites in these cells.

Human promyelocytic leukemia (HL-60) cells contain appreciable levels of MPO.¹⁸¹ We found that incubation of HL-60 cells with HQ (10 μM) or BT (10 μM) can result in alkylation of cellular proteins and cytotoxicity.^{182,183} This cytotoxicity and alkylation of HL-60 cells was potentiated in the presence of hydrogen peroxide, indicating that MPO may be involved in the bioactivation of HQ to the reactive 1,4-BQ. Formation of 1,4-BQ was confirmed by the presence of a GSH-conjugate that co-elutes with the standard 1,4-BQ-GSH conjugate during HPLC analysis. We also found that incubation of HL-60 cells with HQ (10 μM) or BT (10 μM) results in a 2- and 4-fold increase in 8-OHdG formation in DNA, respectively¹⁸³ (Fig. 7). The increase in 8-OHdG formation, however, is transient, and prolonged incubation of these cells results in a drop in 8-OHdG levels in DNA to steady-state levels, indicating that these cells are also equipped with an efficient repair mechanism for oxidative DNA damage. These results suggest that alkylation of cellular proteins and oxidative DNA-damage induced by BZ-metabolites in HL-60 cells may contribute to cytotoxic and genotoxic events in these cells. They also provide the first direct evidence that BZ metabolites could produce mutations via oxidative modification of DNA.



The physiological significance of the reactions of phenoxy radicals with GSH and the subsequent redox cycling of thiyl radicals, in BZ-induced toxicity remains to be determined. We found that red blood cell free bone marrow cells contain low levels of GSH ($1 \text{ nmol}/10^6 \text{ cells}$).¹⁹¹ Smart and Zannoni¹⁹¹ found that the total GSH content of guinea pig bone marrow (unperfused) is approximately in the range of 20–25 nmol/mg protein, which is similar to the hepatic GSH levels (27–28 nmol/mg protein). This indicates that the majority of bone marrow GSH may be associated with the red blood cell fraction. It is also possible that species differences exist in the GSH levels of bone marrow, which remains to be determined.

The peroxidation of lipids is commonly described as an oxidative, oxygen-dependent deterioration of fats, particularly unsaturated fatty acids.^{192,193} Lipid peroxidation can be initiated by abstraction of an H atom from unsaturated fatty acids. This can be achieved either enzymatically as described earlier for AA oxygenation by PGS, or by lipoxygenase or by reaction with another free radical. The addition of oxygen yields a lipid peroxyl radical, which is considered a hallmark of peroxidizing lipids. The peroxy radical combines with the hydrogen atom that it abstracts to give a lipid hydroperoxide, R-OOH. An alternative fate of peroxyl radicals is to form cyclic peroxides. Pure lipid hydroperoxides are fairly stable molecules at physiologic temperatures, but they rapidly decompose in the presence of transition-metal complexes. This results in the fission of O-O bond to form an alkoxy radical.



Peroxyl radicals seem to be less reactive than alkoxyl radicals.¹⁹⁴ In both cases, however, the formation of radical products will stimulate the chain reaction of lipid peroxidation by causing more initiation. β -Scission, a well-known reaction of alkoxyl radicals, leads to the production of compounds containing the carbonyl group $C=O$, particularly aldehydes such as malondialdehyde and 4-hydroxy nonenal. These aldehydes can also readily attack macromolecules such as DNA and protein, which then results in covalent binding as well as intra- and inter-molecular crosslinks of DNA and proteins.^{192,193,195-198} In addition, lipid peroxidation products such as PGE_2 are potent regulators of hematopoiesis.⁵³

It is interesting that HRP-catalyzed oxidation of PH in the presence of AA results in rapid oxygen uptake (Table 2) and conjugated-diene formation.^{40,190} However, HQ and CAT were found to be inactive in this system. It appears that the phenoxyl radicals formed in this system can efficiently abstract a hydrogen atom from AA and induce lipid peroxidation. Baumann *et al.*¹⁹⁹ recently analyzed the products of arachidonic acid in this reaction and found that 90% of the products co-chromatographed with 15-HPETE and 15-HETE, resembling a 15-lipoxygenase-catalyzed pathway.

Benzene administration to rats has been shown to induce lipid peroxidation in both liver and bone marrow of rats.^{33,34,53} It is possible that the phenoxyl radicals and/or oxygen radicals generated during BZ metabolism could contribute to the observed lipid peroxidation following BZ administration.

CONCLUSIONS

This review indicates that a good deal of information is already available in the literature that documents the ability of BZ to induce free radical formation in vivo. However, the role these free radicals play in BZ-induced myelotoxicity and carcinogenesis remains to be determined. Figure 9 summarizes the possible mechanisms of free radical formation, during BZ metabolism that can result in damage to the cellular macromolecules. Free radical formation in bone marrow may occur either during peroxidative metabolism (catalyzed by MPO, EPO, and perhaps PGS) or during auto-oxidation of BZ's phenolic metabolites. The interactions of these radicals with cellular thiols and lipids may initiate oxidative damage and lipid peroxidation. Oxygen free radicals may also be formed by stimulation of the membrane-bound NADPH-oxidase activity of phagocytic bone marrow cells. Active oxygen species such as $HO^\bullet$ and 1O_2 may bind to DNA, resulting in the formation of hydroxylated adducts of bases such as 8-OHdG. Therefore, free radical-mediated DNA damage may contribute to the production of the chromo-

somal aberrations that have been observed in humans following exposure to BZ and the subsequent development of leukemia. Free radical formation in liver, a secondary target organ for BZ-toxicity, can also occur provided cellular defenses such as GSH are depleted.

Acknowledgements — Supported by NIH grants P42 ES04705 and P30 ES01896 (MTS) and ROES 04112 (DR) and the University of California. Tobacco-related Disease Research Program (DE). We thank Dr. P. Kolachana for analyzing the HL-60 cells for the presence of 8-OHdG in their DNA. We also thank P. Doane Setzer for drawing figures with the use of Slidewrite 3.1 graphics software.

REFERENCES

1. Toxicological Profile for Benzene, by Agency for Toxic Substances and Disease Registry, U.S. Public Health Services; 1989.
2. Holmberg, B.; Lundberg, P. Benzene: Standards, occurrence and exposure. *Amer. J. Ind. Med.* 7:375-383; 1983.
3. Wallace, L. A.; Pellizzari, E.; Hartwell, T.; Sparacino, C.; Sheldon, L.; Zelon, H. Personal exposure to volatile organic compounds: I. Direct measurement in breathing-zone air, drinking water, food and exhaled breath. *Environ. Res.* 35:293-319; 1984.
4. Wallace, L. A.; Pellizzari, E. D. Personal exposures and breath concentrations of benzene and other volatile hydrocarbons for smokers and non-smokers. *Toxicol. Lett.* 35:113-116; 1986.
5. Wallace, L. A. Major sources of benzene exposure. *Environ. Hlth. Perspect.* 82:165-169; 1989.
6. Wallace, L. A. The exposure of general population to benzene. *Cell Biol. Toxicol.* 5:297-314; 1989.
7. Rinsky, R. A.; Smith, A. B.; Hornung, R.; Folloon, T. G.; Young, R. J.; Okun, A. H.; Landigian, P. J. Benzene and leukemia: An epidemiological risk assessment. *The New Engl. J. Med.* 316:1044-1050; 1987.
8. Austin, H.; Delzell, E.; Cole, P. Benzene and leukemia: A review of the literature and a risk assessment. *Amer. J. Epidemiol.* 127:419-439; 1988.
9. Aksoy, M. Hematotoxicity and carcinogenicity of benzene. *Environ. Hlth. Perspect.* 82:193-197; 1989.
10. Cooper, K. R.; Snyder, R. Benzene metabolism (Toxicokinetics and the molecular aspects of benzene toxicity). In: Aksoy, M., ed. *Benzene carcinogenicity*. Boca Raton, FL: CRC Press; 1988: 35-58.
11. Kalf, G. F. Recent advances in the metabolism and toxicity of benzene. *CRC Crit. Rev. Toxicol.* 18:141-159 1937.
12. Smith, M. T.; Yager, J. W.; Steinmetz, K. L.; Eastmond, D. A. Peroxidase-dependent metabolism of benzene's phenolic metabolites and its potential role in benzene toxicity and carcinogenicity. *Environ. Hlth. Perspect.* 82:23-29; 1989.
13. Sabourin, P. J.; Bechtold, W. E.; Griffith, W. C.; Birnbaum, L. S.; Lucier, G.; Henderson, R. F. Effect of exposure concentration, exposure rate and route of administration on metabolism of benzene by F344/N rats and B6C3F1 mice. *Toxicol. Appl. Pharmacol.* 99:421-444; 1989.
14. Huff, J. E.; Haseman, J. K.; DeMarini, D. M.; Eustis, S.; Maronpot, R. R.; Peters, A. C.; Persing, R. L.; Chrisp, C. E.; Jacobs, A. C. Multiple-site carcinogenicity of benzene in Fischer 344 rats and B6C3F1 mice. *Environ. Hlth. Perspect.* 82:125-163; 1989.
15. Porteus, J. W.; Williams, R. T. Studies in detoxication 20. The metabolism of benzene II. The isolation of phenol, catechol, quinol and hydroxyquinol from the ethereal sulphate fraction of the urine of rabbits receiving benzene orally. *Biochem. J.* 44:56-61; 1949.
16. Parke, D. V.; Williams, R. T. Studies in detoxication 49. The metabolism of benzene containing [^{14}C]benzene. *Biochem. J.* 54:231-238; 1953.
17. Parke, D. V.; Williams, R. T. The metabolism of benzene (a)

- The formation of phenylglucuronide and phenylsulphuric acid from [^{14}C]benzene. (b) The metabolism of [^{14}C]phenol. *Biochem. J.* **55**:337-340; 1953.
18. Gad-El-Karim, M. M.; Sadagopa Ramanujam, V. M.; Legator, M. S. *Trans,trans*-muconic acid, an open-chain urinary metabolite of benzene in mice. Quantitation by high pressure liquid chromatography. *Xenobiotica* **15**:211-220; 1985.
 19. Sabourin, P. J.; Bechtold, W. E.; Birnbaum, L. S.; Lucier, G.; Henderson, R. F. Differences in the metabolism and disposition of inhaled [^3H]benzene by F344/N rats and B6C3F1 mice. *Toxicol. Appl. Pharmacol.* **94**:128-140; 1988.
 20. Porteus, J. W.; Williams, R. T. Studies in detoxication 19. The metabolism of benzene I (a) The determination of phenol in urine with 2,6-dichloroquinonechloroimide. (b) The excretion of phenol glucuronic acid and ethereal sulphate by rabbits receiving knzene and phenol. (c) Observation on the determination of catechol, quinol and muconic acid in urine. *Biochem. J.* **44**:46-55; 1949.
 21. Inoue, O.; Seiji, K.; Nakatsuka, H.; Watanabe, T.; Yin, S. N.; Li, G.-L.; Cai, S.-X.; Jin, C.; Ikeda, M. Excretion of 1,2,4-benzenetriol in the urine of workers exposed to benzene. *Br. J. Ind. Med.* **46**:559-565; 1989.
 22. Tunek, A.; Plan, K. L.; Przybylski, M.; Oesch, F. Multistep metabolic activation of benzene. Effects of superoxide dismutase on covalent binding to microsomal macromolecules, and identification of glutathione conjugates using high pressure liquid chromatography and field desorption mass spectrometry. *Chem.-Biol. Interacts.* **33**:1-17; 1980.
 23. Hinson, J. A.; Freeman, J. P.; Potter, D. W.; Mitchum, R. K.; Evans, F. E. Mechanism of microsomal metabolism of benzene to phenol. *Mol. Pharmacol.* **27**:574-577; 1985.
 24. Gonasun, L. M.; Witmer, C. M.; Kocsis, J. J.; Snyder, R. Benzene metabolism in mouse liver microsomes. *Toxicol. Appl. Pharmacol.* **26**:398-406; 1973.
 25. Gorsky, L. D.; Coon, M. J. Evaluation of the role of free hydroxyl radicals in the cytochrome P-450 catalyzed oxidation of benzene and cyclohexanol. *Drug Metab. Disp.* **13**:169-174; 1985.
 26. Lunte, S. M.; Kissinger, P. T. Detection and identification of sulfhydryl conjugates of p-benzoquinone in microsomal incubations of benzene and phenol. *Chem.-Biol. Interacts.* **47**:195-212; 1983.
 27. Griffiths, J. C.; Kalf, G. F.; Snyder, R. The metabolism of benzene and phenol by a reconstituted purified phenobarbital-induced rat liver mixed-function oxidase system. *Adv. Exp. Med. Biol.* **197**:213-222; 1986.
 28. Koop, D. R.; Laetham, C. L.; Schneir, G. G. Identification of ethanol-inducible P 450 isozyme 3a (P450 IIE1) as a benzene and phenol hydroxylase. *Toxicol. Appl. Pharmacol.* **98**:278-288; 1989.
 29. Tunek, A.; Platt, K. L.; Bentley, P.; Oesch, F. Microsomal metabolism of benzene to species irreversibly binding to microsomal protein and effects of modifications of this metabolism. *Mol. Pharmacol.* **14**:920-929; 1978.
 30. Wallin, H.; Melin, P.; Schelin, C.; Jergil, B. Evidence that covalent binding of metabolically activated phenol to microsomal protein is caused by oxidized products of hydroquinone and catechol. *Chem.-Biol. Interacts.* **55**:335-346; 1985.
 31. Irons, R. D. Quinones as toxic metabolites of benzene. *J. Toxicol. Environ. Hlth.* **16**:673-678; 1985.
 32. Lariano, L.; Goldstein, B. D.; Wia, G. Formation of muconaldehyde, an open-ring metabolite of benzene, in mouse liver microsomes: A novel pathway for toxic metabolites. *Proc. Natl. Acad. Sci. (USA)* **83**:8356-8360; 1986.
 33. Uysal, M.; Yalcin, A. S.; Kocak-Toker, N.; Keyer-Uysal, M.; Aykac, G. Lipid peroxidation in liver and plasma of rats treated with benzene. *IRCS Med. Sci.* **14**:772; 1986.
 34. Khan, W. A.; Gupta, A.; Shanker, U.; Pandya, K. P. Involvement of iron and free radicals in benzene toxicity. *Biochem. Pharmacol.* **33**:2009-2112; 1984.
 35. Khan, S.; Kramanumrany, R.; Pandya, K. P. Generation of hydroxyl radicals during benzene toxicity. *Biochem. Pharmacol.* **39**:1393-1395; 1990.
 36. Slater, T. F. Free-radical mechanisms in tissue injury. *Biochem. J.* **222**:1-15; 1984.
 37. Pryor, W. A. Free radical biology: Xenobiotics, cancer and aging. *Ann. NY Acad. Sci.* **393**:1-22; 1982.
 38. Demopoulos, H. B.; Pietronigro, D. D.; Flamm, E. S.; Seligman, M. L. The possible role of free radical reactions in carcinogenesis. *J. Env. Pathol. Toxicol.* **3**:273-303; 1980.
 39. Nagata, C.; Kodama, M.; Yoshikazu, I.; Kimura, T. Free radicals produced from chemical carcinogens and their significance in carcinogenesis. In: R. A. Floyd, ed. *Free radicals and cancer*. New York: Marcel Dekker Inc. 1982:1-62.
 40. O'Brien, P. J. Radical formation during the peroxidase-catalyzed metabolism of carcinogens and xenobiotics: The reactivity of these radicals with GSH, DNA, and unsaturated lipid. *Free Radical Biol. Med.* **4**:169-183; 1988.
 41. O'Brien, P. J. Free radical-mediated chemical carcinogenesis. *Ann. NY Acad. Sci.* **534**:552-564; 1988.
 42. Myers, L. S. Free radical damages of nucleic acids and their components. In: Pryor, W. ed. *Free radicals in biology*. Vol. IV. New York: Academic Press; 1982:95-115.
 43. Brown, K.; Fridovich, I. DNA-strand scission by enzymatically generated oxygen radicals. *Arch. Biochem. Biophys.* **206**:414-419; 1981.
 44. Imlay, T. A.; Linn, S. DNA damage and oxygen radical toxicity. *Science* **240**:1302-1309; 1988.
 45. Kasai, H.; Nishimura, S. Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. *Nucleic Acids Res.* **12**:2137-2145; 1984.
 46. Ames, B. N. Carcinogens and anti-carcinogens. In: Shankel, D. M.; Hartman, P. E.; Kado, T.; Hollaender, A. eds. *New York: Plenum Press; Antimutagenesis and anticarcinogenesis mechanisms*. Vol. 39. 1985:7-35.
 47. Frenkel, K.; Cummings, A.; Solomon, J.; Cadet, J.; Steinberg, J. J.; Teebor, G. W. Quantitative determination of the 5-(hydroxymethyl)uracil moiety in the DNA of γ -irradiated cells. *Biochemistry* **24**:4527-4533; 1985.
 48. Ames, B. N. Dietary carcinogens and anticarcinogens—Oxygen radicals and degenerative diseases. *Science* **221**:1256-1264; 1983.
 49. Cerutti, P. A. Tumor promotion by oxidants. In: Iversen, O. V., ed. *Theories of carcinogenesis*. Washington: Hemisphere Publishing; 1988:221-230.
 50. Meneghini, R. Genotoxicity of active oxygen species in mammalian cells. *Mutat. Res.* **195**:215-230; 1988.
 51. Yu, L. W.; Lamano, L.; Duncan, S.; Hartwick, R. A.; Wia, G. High performance liquid chromatography analysis of the thiobarbituric acid adducts of malonaldehyde and *trans,trans*-muconaldehyde. *Anal. Biochem.* **156**:326-333; 1986.
 52. Witz, G.; Lawrie, N. J.; Zaccaria, A.; Ferran, Jr., H. E.; Goldstein, B. D. The reaction of 2-thiobarbituric acid with biologically active α,β -unsaturated aldehydes. *J. Free Radical Biol. Med.* **2**:33-39; 1986.
 53. Gaido, K. W.; Wierda, D. Suppression of bone marrow stromal cell function by benzene and hydroquinone is ameliorated by indomethacin. *Toxicol. Appl. Pharmacol.* **89**:378-390; 1987.
 54. Laskin, D. L.; MacEashem, L.; Snyder, R. Activation of phagocytes following benzene treatment of mice. *Environ. Hlth Perspect.* **82**:75-79; 1989.
 55. Anwar, W. A.; Au, W. W.; Legator, M. S.; Ramanujam, V. M. S. Effect of dimethylsulfoxide on the genotoxicity and metabolism of benzene in vivo. *Carcinogenesis* **10**:441-445; 1989.
 56. Ekstrom, T.; Margareta, W.; Krontev, T.; Hogberg, J. Recovery of malondialdehyde in urine as a 2,4-dinitrophenylhydrazine derivative after exposure to chloroform or hydroquinone. *Chem.-Biol. Interacts.* **67**:25-31; 1988.
 57. Stenius, U.; Margareta, W.; Rannug, A.; Wallis, S.; Lundberg, I.; Hogberg, J. The role of GSH depletion and toxicity in hydroquinone-induced development of enzyme-altered foci. *Carcinogenesis* **10**:593-599; 1989.
 58. Anundi, I.; Hogberg, J.; Stead, A. H. GSH depletion in isolated hepatocytes: Its relation to lipid peroxidation and cell damage. *Acta Pharmacol. Toxicol.* **45**:45-51; 1979.
 59. Horton, A. A.; Fairhurst, S. Lipid peroxidation and mecha-

- nisms of toxicity. *CRC Crit. Rev. Toxicol.* **18**:27-29; 1987.
60. Karr, F. W. *NTP Technical Report on the toxicology and carcinogenesis studies of hydroquinone* (CAS No. 123-31-9) in F344/N Rats and B6C3F₁ Mice (Gavage Studies). *NTP TR*: 366; NIH Publication No. 89-2821; 1988.
 61. Kariya, K.; Lee, E. W.; Hirouchi, M.; Hosokawa, M.; Sayo, M. Purification and some properties of peroxidases of rat bone marrow. *Eiochem. Biophys. Acta.* **99**:95-101; 1987.
 62. Pirozzi, S. J.; Renz, J. F.; Kalf, G. F. The prevention of benzene-induced genotoxicity in mice by indomethacin. *Mutat. Res.* **222**:291-298; 1989.
 63. Kalf, G. F.; Schlosser, M. J.; Ren, J. F.; Pirozzi, S. J. Revention of benzene-induced myelotoxicity by nonsteroidal anti-inflammatory drugs. *Environ. Hlth. Perspect.* **82**:57-64; 1989.
 64. Schlosser, M. J.; Kalf, G. F. Metabolic activation of hydroquinone by macrophage peroxidase. *Chem.-Biol. Interactions.* **72**:191-207; 1989.
 65. Schlosser, M. J.; Shurina, R. D.; Kalf, G. F. Metabolism of phenol and hydroquinone to reactive products by macrophage peroxidase or purified prostaglandin H synthase. *Environ. Hlth. Perspect.* **82**:229-237; 1989.
 66. Dawson, J. H. Probing structure-function relations in heme-containing oxygenases and peroxidases. *Science* **240**:433-439; 1988.
 67. Saunders, B. C.; Holmes-Siedle, A. G.; Stark, B. P. Peroxidase: *The properties and uses of a versatile enzyme and some related catalysts*. Washington: Butterworths; 1964.
 68. LaMar, G. M.; de Ropp, J. S.; Smith, K. M.; Laungry, K. C. Proton Nuclear Magnetic resonance investigation of the electronic structure of compound I of horseradish peroxidases. *J. Eiol. Chem.* **256**:237-243; 1981.
 69. Dolphin, D.; Forman, A.; Borg, D. C.; Fajer, J.; Felton, R. H. Compounds I of catalase and horseradish peroxidase: Π -cation radicals. *Proc. Natl. Acad. Sci. (USA)* **68**:614-618; 1971.
 70. Kaneko, Y.; Tamura, M.; Yamazaki, I. Formation of porphyrin Π -cation radical in zinc-substituted horseradish peroxidase. *Biochemistry* **19**:5795-5799; 1980.
 71. Hashimoto, S.; Tatsuno, Y.; Kitagawa, T. Resonance raman evidence for oxygen exchange between the Fe $N=O$ heme and bulk water during enzymatic catalysis of horseradish peroxidase and its relation with the heme-linked ionization. *Proc. Natl. Acad. Sci. (USA)* **83**:2417-2421; 1986.
 72. Makino, R.; Uno, T.; Nishimura, Y.; Mizuka, T.; Tsuboi, M.; Ishimura, Y. Coordination structures and reactivities of compound II in iron and manganese horseradish peroxidases: A resonance raman study. *J. Eiol. Chem.* **261**:8376-8382; 1986.
 73. Yamazaki, I.; Mason, H. S.; Piette, L. Identification by electron paramagnetic resonance spectroscopy, of free radicals generated from substrates by peroxidase. *J. Biol. Chem.* **235**:2444-2449; 1960.
 74. Yamazaki, I.; Mason, H. S.; Piette, L. Identification of intermediate substrate free radicals formed during peroxidatic oxidations by electron paramagnetic resonance spectroscopy. *Eiochem. Biophys. Res. Commun.* **1**:336-337; 1959.
 75. Yamazaki, I. One-electron and two-electron transfer mechanisms in enzymic oxidation-reduction reactions. *Adv. Biophys.* **2**:33-76; 1971.
 76. Dugad, L. B.; LaMar, G. N.; Lee, H. C.; Ikeda-Saito, M.; Booth, K. S.; Caughey, W. S. A nuclear overhauser effect study of the active site of myeloperoxidase: Structural similarity of the prosthetic group to that on lactoperoxidase. *J. Biol. Chem.* **265**:7173-7179; 1990.
 77. Nicholl, A. W.; Angel, L. A.; Moon, T.; Clezy, P. S. Lactoperoxidase haem: an iron-porphyrin thiol. *Biochem. J.* **247**:147-150; 1987.
 78. Odajima, T.; Yamazaki, I. Myeloperoxidase of the leukocyte of normal blood. I. Reaction with hydrogen peroxide. *Eiochem. Biophys. Acta.* **206**:71-77; 1970.
 79. Harrison, J. E.; Araisio, T.; Palcic, M. M.; Dunford, H. B. Compound I of myeloperoxidase. *Biochem. Biophys. Res. Commun.* **94**:34-40; 1980.
 80. Odajima, T. Myeloperoxidase of the leukocyte of normal blood: Nature of the prosthetic group of myeloperoxidase. *J. Eiol. Chem.* **87**:379-391; 1980.
 81. Eastmond, D. A.; Smith, M. T.; Ruzo, L. O.; Ross, D. Metabolic activation of phenol by human myeloperoxidase and horseradish peroxidase. *Mol. Pharmacol.* **30**:674-679; 1986.
 82. Subrahmanyam, V. V.; Kolachana, P.; Smith, M. T. Effect of phenol and catechol on the kinetics of human myeloperoxidase-dependent hydroquinone metabolism. In: Witter, C. M.; Snyder, R.; Jollow, J.; Kalf, G. F.; Kocsis, J. J.; Sipes, I. G., eds. *Biological reactive intermediates IV: Molecular and cellular effects and their impact on human health, advances in biol. med.* Vol. 283. New York: Plenum Press; 1991:377-381.
 83. Subrahmanyam, V. V.; Kolachana, P.; Smith, M. T. Hydroquinone metabolism by human myeloperoxidase: Mechanisms of stimulation by other phenolic compounds. *Arch. Eiochem. Eiophys.* **286**:76-84; 1991.
 84. Sadler, A.; Subrahmanyam, V. V.; Ross, D. Oxidation of catechol by horseradish peroxidase and human leukocyte peroxidase: Reactions of o-benzoquinone and o-benzosemiquinone. *Toxicol. Appl. Pharmacol.* **93**:62-71; 1988.
 85. Danner, D. J.; Brignac, P. J.; Archeneaux, D.; Patel, V. The oxidation of phenol and its reaction product by horseradish peroxidase and hydrogen peroxide. *Arch. Biochem. Biophys.* **156**:759-763; 1973.
 86. Sawahata, T.; Neal, R. A. Horseradish peroxidase-mediated oxidation of phenol. *Eiochem. Biophys. Res. Commun.* **109**:988-994; 1982.
 87. Subrahmanyam, V. V.; O'Brien, P. J. Phenol oxidation products, formed by a peroxidase reaction, that bind to DNA. *Xenobiotica* **15**:873-885; 1985.
 88. Subrahmanyam, V. V.; O'Brien, P. J. Peroxidase-catalyzed phenol binding to DNA. *Xenobiotica* **15**:859-871; 1985.
 89. McGinn, L. G.; Subrahmanyam, V. V.; Moore, G. A.; O'Brien, P. J. Peroxidase-catalyzed 3-(S-glutathionyl)-p,p'-biphenol formation. *Chem.-Biol. Interactions.* **60**:85-99; 1986.
 90. Kalyanaraman, B.; Sealy, R. C. Electron-spin resonance-spin stabilization in enzymatic systems: Detection of semiquinones produced during peroxidatic oxidation of catechols and catecholamines. *Eiochem. Biophys. Res. Commun.* **106**:1119-1125; 1982.
 91. Kalyanaraman, B.; Felix, C. C.; Sealy, R. C. Semiquinone anion radicals of catechol(amine)s, catechol estrogens and their metal ion complexes. *Environ. Hlth. Perspect.* **64**:185-198; 1985.
 92. Ganong, W. F. *Review of medical physiology*, 11th ed. Los Altos, CA: Lange Medical Publications; 1983:415.
 93. Begemann, H.; Rastetter, J., eds. *Atlas of clinical hematology*. Berlin: Springer Verlag; 1979.
 94. Tavassoli, M.; Yoffey, J. M., eds. *Bone marrow structure and function*. New York: Alan R. Liss, Inc.; 1983:140-143.
 95. Subrahmanyam, V. V.; Sadler, A.; Suba, E.; Ross, D. Stimulation of in vitro bioactivation of hydroquinone by phenol in bone marrow cells. *Drug Metab. Disp.* **17**:348-350; 1989.
 96. Twerdok, L. E.; Trush, M. A. Neutrophil-derived oxidants as mediators of chemical activation in bone marrow. *Chem.-Biol. Interactions.* **65**:261-273; 1988.
 97. Test, S. T.; Weiss, S. J. The generation and utilization of chlorinated oxidants by human neutrophils. *Adv. Free Radical Biol. Med.* **2**:91-116; 1986.
 98. Bellavite, P. The superoxide-forming enzymatic system of phagocytes. *Free Radical Biol. Med.* **4**:225-261; 1988.
 99. Suzuki, Y.; Lehrer, R. I. NADPH-oxidase activity in human neutrophils stimulated by phorbol myristate acetate. *J. Clin. Invest.* **66**:1409-1418; 1980.
 100. Roghani, M.; Da Silva, C.; Guvelli, D.; Castagna, M. Benzene and toluene activate protein kinase C. *Carcinogenesis* **81**:105-1107; 1987.
 101. Da Silva, C.; Fan, X.; Castagna, M. Benzene-mediated protein kinase C activation. *Environ. Hlth. Perspect.* **82**:91-95; 1989.
 102. Rovera, G.; Santoli, D.; Damsky, C. Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when mated with a phorbol diester. *Proc. Natl. Acad. Sci. (USA)* **76**:2779-2783; 1979.

103. Newburger, P. E.; Tauber, A. I. Heterogenous pathways of oxidizing radical production in human neutrophils and the HL-60 cell line. *Pediatr. Res.* **16**:856-860; 1982.
104. butter, D.; Caldwell, A. B.; Morin, M. J. Dissociation of protein kinase C activation from phorbol ester-induced maturation of HL-60 leukemia cells. *J. Biol. Chem.* **260**:5979-5984; 1985.
105. Morin, M. J.; butter, D.; Rasmussen, H.; Sartorelli, A. C. Disparate effects of activators of protein kinase C on HL-60 leukemia cell differentiation. *J. Biol. Chem.* **262**:11758-11763; 1987.
106. Yamamoto, S.; Gotoh, H.; Aizu, E.; Kato, R. Failure of 1-oleoyl-2-acetyl-glycerol to mimic the cell-differentiating action of 12-O-tetradecanoyl-phorbol-13-acetate in HL-60 cells. *J. Biol. Chem.* **260**:14230-14234; 1985.
107. Carlson, C.; O'Connor, A.; Kalf, G. Differentiation of HL-60 promyelocytes to granulocytes induced via the activation of protein kinase-C by benzene. *FASEB J.* **5** (Part II), abstract no. 5031: A1238; 1991.
108. Oliviera, N. L.; Kalf, G. F. Hydroquinone inhibits the phorbol ester-induced differentiation of HL-60 promyelocyte to macrophage. *Proc. Amer. Assoc. Cancer Res.* **31**: abstract no. 217; 1990.
109. Kalir, A.; Bessler, H.; Braun, R.; Gitter, S.; Djaldeti, M. Benzene-derived free radical-A possible mediator of its carcinogenicity. I. Ultrastructural and functional studies on the effect of benzene on human white blood cells and its possible prevention. *Isr. J. Med. Sci.* **25**:421-428; 1989.
110. Eastmond, D. A.; Smith, M. T.; Irons, R. D. An interaction of benzene metabolites reproduces the myelotoxicity observed with benzene exposure. *Toxicol. Appl. Pharmacol.* **91**:85-95; 1987.
111. O'Brien, P. J.; Subrahmanyam, V. V.; Fournay, R. M.; Davidson, W. S.; Rahimula, A. D.; Tsuruta, Y. One-electron oxidation in cell toxicity. In: Boobis, A. R.; Caldwell, J.; Dematties, F.; Elcombe, C. R., & *Microsomes and drug oxidations*. London and Philadelphia: Taylor & Francis; 1985:284-295.
112. Eastmond, D. A.; French, R. C.; Ross, D.; Smith, M. T. Metabolic activation of 1-naphthol and phenol by a simple superoxide-generating system and human leukocytes. *Chem.-Biol. Interactions.* **63**:47-62; 1987.
113. Andrews, L. S.; Sasame, H. A.; Gillette, J. R. H-Benzene metabolism in rabbit bone marrow. *Life Sci.* **25**:567-572; 1979.
114. Gollmer, L.; Graf, H.; Ullrich, V. Characterization of the benzene monooxygenase system in rabbit bone marrow. *Biochem. Pharmacol.* **33**:3597-3602; 1984.
115. Schneir, G. G.; Laetham, C. L.; Koop, D. R. Identification and induction of cytochrome P-450, P-450 IIE1 and P-450 IA1 in rabbit bone marrow. *J. Pharmacol. Exp. Therap.* **251**:790-797; 1989.
116. Subrahmanyam, V. V.; McGirt, L. G.; O'Brien, P. J. Peroxidase/hydrogen peroxide- or bone marrow homogenate/hydrogen peroxide-mediated activation of phenol and binding to protein. *Xenobiotica* **20**:1369-1378; 1990.
117. Bhat, R. V.; Subrahmanyam, V. V.; Sadler, A.; Ross, D. Bioactivation of catechol in rat and human bone marrow cells. *Toxicol. Appl. Pharmacol.* **94**:297-304; 1988.
118. Dexter, T. M.; Coutinho, L. H.; Spooner, E.; Heyworth, C. M.; Daniel, C. P.; Schiro, R.; Chang, J.; Allen, T. D. Stromal cells in hemopoiesis. In: Bock, G.; Marsh, J., eds. *Molecular control of haemopoiesis*. New York: John Wiley & Sons; 1990:76-95.
119. Thomas, D. J.; Reasor, M. J.; Wierda, D. Macrophages regulation of myelopoiesis is altered by exposure to the benzene metabolite hydroquinone. *Toxicol. Appl. Pharmacol.* **97**:440-443; 1989.
120. Thomas, D. J.; Sadler, A.; Subrahmanyam, V. V.; Siegel, D.; Reasor, M. J.; Wierda, D.; Ross, D. Bone marrow stromal cell bioactivation and of the benzene metabolite hydroquinone: Comparison of macrophages and fibroblastoid cells. *Mol. Pharmacol.* **37**:255-262; 1990.
121. Ross, D.; Siegel, D.; Gibson, N. W.; Pacheco, D.; Thomas, D. J.; Reasor, M.; Wierda, D. Activation and deactivation of quinones catalyzed by DT-diaphorase. Evidence for bioreductive activation of diaziquone (AZQ) in human tumor cells and detoxification of benzene metabolites in bone marrow stroma. *Free Radical Res. Commun.* **8**:373-381; 1990.
122. Smart, R. C.; Zannoni, V. G. DT-diaphorase and peroxidase influence the covalent binding of metabolites of phenol, the major metabolite of benzene. *Mol. Pharmacol.* **26**:105-111; 1984.
123. Eling, T. E.; Thompson, D. C.; Fourtman, G. L.; Curtis, J. F.; Hughes, M. F. Prostaglandin H synthase and xenobiotic oxidation. *Ann. Rev. Pharmacol. Toxicol.* **30**:1-45; 1990.
124. Marnett, L. J., ed. *Arachidonic acid metabolism and tumor initiation*. Boston: Martinus Nijhoff Publishing; 1985.
125. Gale, P. H.; Egan, R. W. Prostaglandin endoperoxide synthase-catalyzed oxidation reactions. In: Pryor, W. A., ed. *Free radicals in biology*. Vol. VI. New York: Academic Press; 1984: 1-38.
126. Ivins, J. K.; Penning, T. M. Radiochemical detection of dihydrodiol dehydrogenase: Distribution of enzyme in male sprague-dawley rat tissues and its sensitivity to inhibition by indomethacin and 6-methoxyprogesterone acetate. *Cancer Res.* **47**:680-684; 1987.
127. Rittenhouse-Simmons, S. Indomewin-induced accumulation of diglyceride in activated human platelets: The role of diglyceride lipase. *J. Biol. Chem.* **255**:2259-2262; 1980.
128. Alino, S. F.; Hilario, E. Effect of indomethacin and acetylsalicylic acid (ASA) on peroxidase activity of gastric mucosa of rat. *Cellular Mol. Biol.* **33**:29-33; 1987.
129. Alino, S. F.; Hilario, E.; Alvarez, A. Is the gastric lesion correlated with the inhibition of tissular peroxidase activity induced by indomethacin? *Cellular Mol. Biol.* **34**:351-359; 1988.
130. Zilletti, L.; Ciuffi, M.; Moneti, G.; Franchi-Micheli, S.; Valoti, M.; Sgaragli, P. Peroxidase catalysed formation of prostaglandins from arachidonic acid. *Biochem. Pharmacol.* **38**: 2429-2439; 1989.
131. Christ, E. J.; VanDorp, D. A. Comparative aspects of prostaglandin biosynthesis in animal tissues. *Biochim. Biophys. Acta.* **270**:537-545; 1972.
132. Ziboh, V. A.; Lord, J. T.; Kursunoglu, I.; Poirier, J.; Yunis, A. Alteration of prostaglandin biosynthesis in rat chloroleukemic tumor. *Cancer Res.* **37**:3974-3980; 1977.
133. Kojima, A.; Shiraki, M.; Takahashi, R.; Orimo, H.; Morita, I.; Murota, S. Prostaglandin D₂ is the major prostaglandin of arachidonic acid metabolism in rat bone marrow homogenate. *Prostaglandins* **20**:171-176; 1980.
134. Michel, L.; Pitton, C.; Prost, C.; Masse, J.; Mencia-huerta, J.; Burtin, C.; Maclof, J.; Breton-gorius, J.; Benveniste, J.; Duberret, L. Prostaglandin D₂ generation in mouse bone marrow-derived mast cells exposed to dexamethasone is associated with endogenous peroxidase activity. *Lab. Invest.* **59**:613-624; 1988.
135. Witz, G.; Rao, G. S.; Goldstein, B. D. Short-term toxicity of trans,trans-muconaldehyde. *Toxicol. Appl. Pharmacol.* **80**:511-516 1985.
136. Lutz, W. K. In vivo covalent binding of organic chemicals to DNA as a quantitative indicator in the process of chemical carcinogenesis. *Mutat. Res.* **65**:289-356; 1979.
137. Lutz, W. K.; Schlatter, C. H. Mechanism of the carcinogenic action of benzene: Irreversible binding to rat liver DNA. *Chem.-Biol. Interactions.* **18**:241-245; 1977.
138. Gill, D. P.; Ahmed, A. E. Covalent binding of [¹⁴C] benzene to cellular nucleic acids. *Biochem. Pharmacol.* **30**:1127-1131; 1981.
139. Artellini, G.; Grill, S.; Colacci, A.; Mazzullo, M.; Prodi, G. In vivo and in vitro binding of benzene to nucleic acids and proteins of various rat and mouse organs. *Cancer Lett.* **28**:159-168; 1985.
140. Rushmore, T.; Snyder, R.; Kalf, G. Covalent binding of benzene and its metabolites to DNA in rabbit bone marrow mitochondria in vitro. *Chem.-Biol. Interactions.* **49**:133-154; 1984.
141. Snyder, R.; Jowa, L.; Witz, G.; Kalf, G.; Rushmore, T. Formation of reactive metabolites from benzene. *Arch. Toxicol.* **60**:61-64; 1987.

142. Jowa, L.; Winkle, S.; Kalf, G.; Win, G.; Snyder, R. Deoxyguanosine adducts formed from benzoquinone and hydroquinone. In: *Biological reactive intermediates*. Vol. III. New York: Plenum Press; 1986:825-832.
143. Latriano, L.; Wia, G.; Goldstein, B. D.; Jeffrey, A. M. Chromatographic and spectrophotometric characterization of adducts formed during the reaction of *trans,trans*-muconaldehyde with ¹⁴C-deoxyguanosine 5'-phosphate. *Environ. Hlth. Perspect.* 82: 249-252; 1989.
144. Pongracz, K.; Kaur, S.; Burlingame, A. L.; Bodell, W. J. Detection of (3'-hydroxy)-3,N⁴-benzetheno-2'-deoxycytidine-3'-phosphate by ³²P-postlabelling of DNA reacted with p-benzoquinone. *Carcinogenesis* 11:1469-1472; 1990.
145. Bauer, H.; Snyder, R. Studies on the formation of adducts formed during the oxidation of the benzene metabolites, 1,2- or 1,4-benzenediol and purine or pyrimidine-3'-monophosphates. *Proc. Amer. Assoc. Cancer Res.* 30: abstract no. 11; 1989.
146. O'Brien, P. J. Free radical-mediated DNA binding. *Environ. Hlth. Perspect.* 64:219-232; 1985.
147. Epe, B.; Metzler, E. Nature of the macromolecular binding of diethylstilbestrol to DNA and protein following oxidation by peroxidase/hydrogen peroxide. *Chem.-Biol. Interacs.* 56:351-362; 1985.
148. Potter, D. W.; Miller, D. W.; Hinson, J. A. Identification of acetaminophen polymerization products catalyzed by horseradish peroxidase. *1. Biol. Chem.* 260:12174-12180.
149. Bauer, H.; Dimitriadis, A.; Snyder, R. An in vivo study of benzene metabolite DNA adduct formation in liver of male New Zealand rabbits. *Arch. Toxicol.* 63:209-213; 1989.
150. Reddy, M. V.; Bleicher, W. T.; Blackburn, G. R.; Mackerer, C. R. DNA adduction by phenol, hydroquinone or benzoquinone in vitro but not in vivo: nuclease P₁-enhanced ³²P-postlabelling of adducts as labelled nucleoside bisphosphates, dinucleotides and nucleoside monophosphates. *Carcinogenesis* 11: 1349-1357; 1990.
151. Reddy, M. V.; Blackburn, G. R.; Schreiner, C. A.; Mehlman, M. A.; Mackerer, C. R. ³²P-analysis of DNA adducts in tissues of benzene-treated rats. *Environ. Hlth. Perspect.* 82:253-257; 1989.
152. Norpoth, K.; Stucker, W.; Krewet, E.; Muller, G. Biomonitoring of benzene exposure by trace analyses of phenylguanine. *Int. Arch. Occup. Environ. Hlth.* 60:163-168; 1988.
153. Dean, B. J. Recent findings on the genetic toxicology of benzene, toluene, xylenes and phenols. *Mutat. Res.* 154:153-181; 1985.
154. Formi, A.; Cappellini, A.; Pacifico, E.; Vigliani, E. C. Chromosome changes and their evolution in subjects with past exposure to benzene. *Arch. Environ. Hlth.* 23:385-391; 1971.
155. Morimoto, K.; Wolff, S. Increase of sister chromatid exchanges and perturbations of cell division kinetics in human lymphocytes by benzene metabolites. *Cancer Res.* 40:1189-1193; 1980.
156. Yardley-Jones, A.; Anderson, D.; Lovell, D. P.; Jenkinson, P. C. Analysis of chromosomal aberrations in workers exposed to low level benzene. *Brit. J. Indust. Med.* 47:48-51; 1990.
157. Tice, R.; Costa, D.; Drew, R. Cytogenetic effects of inhaled benzene on murine bone marrow: Induction of sister chromatid exchanges, chromosomal aberrations and cellular proliferation inhibition in DBA/2 mice. *Proc. Natl. Acad. Sci. (USA)* 77: 2148-2155; 1980.
158. Hecht, F.; Hecht, B. K. Aneuploidy in humans: Dimensions, demography and dangers of abnormal numbers of chromosomes. In: Vig, B. K.; Sandberg, A., & Aneuploidy. *Pan A: Incidence and etiology*. New York: Liss; 1987:9-49.
159. Sandberg, A. A. Aneuploidy in human neoplasia. In: Vig, B. K.; Sandberg, A., eds. *Aneuploidy, Part A: Incidence and etiology*. New York: Liss; 1987:117-134.
160. Let, E. W.; Gamer, C. D.; Johnson, J. T. A proposed role played by benzene itself in the induction of acute cytopenia: Inhibition of DNA synthesis. *Res. Commun. Pathol. Pharmacol.* 60:27-46; 1988.
161. Let, E. W.; Johnson, J. T.; Gamer, C. D. Inhibitory effect of benzene metabolites on nuclear DNA synthesis in bone marrow cells. *1. Toxicol. Environ. Hlth.* 26:277-291; 1989.
162. Irons, R. D.; Heck, H. A.; Moore, B. J.; Murrehead, K. A. Effect of short-term benzene treatment on bone marrow cell cycle kinetics in the rat. *Toxicol. Appl. Pharmacol.* 51:399-409; 1979.
163. Irons, R. D.; Nepton, D. A.; Pfeifer, R. W. Inhibition of lymphocyte transformation and microtubule assembly by quinone metabolites of benzene: Evidence for a common mechanism. *1. Reticulo-endothel. Soc.* 30:359-371; 1981.
164. Irons, R. D.; Nepton, D. A. Effects of the principal hydroxymetabolites of benzene on microtubule polymerization. *Arch. Toxicol.* 45:297-305; 1980.
165. Dizdaroglu, M. Chemical determination of free-radical induced damage to DNA. *Free Radical Biol. Med.* 10:225-242; 1991.
166. Kuchino, Y.; Mori, F.; Kasai, H.; Inoue, H.; Iwai, S.; Miura, K.; Ohtsuka, E.; Nishimura, S. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. *Nature* 237:77-79; 1987.
167. Floyd, R. A. The role of 8-hydroxyguanine in carcinogenesis. *Carcinogenesis* 11:1447-1450; 1990.
168. Biaglow, J. G.; Vames, M. E.; Koch, C. J.; Sridhar, R. The metabolic activation of carcinogenic nitro compounds to oxygen-reactive intermediates. In: Floyd, R. A., ed. *Free radicals and Cancer*. New York: Marcel Dekker; 1982:441-452.
169. Subrahmanyam, V. V.; O'Brien, P. J. Peroxidase-catalyzed oxygen activation by arylamine carcinogens and phenol. *Chem.-Biol. Interacs.* 56:185-199; 1985.
170. Sawada, Y.; Iyanagi, T.; Yamazaki, I. Relation between redox potentials and rate constants in reactions coupled with the system oxygen-superoxide. *Biochemistry* 14:3761-3764; 1975.
171. Kasai, H.; Nishimura, S. Hydroxylation of deoxyguanosine at the C-8 position by polyphenols and aminophenols in the presence of hydrogen peroxide and ferric iron. *Jap. J. Cancer Res.* 75:565-566; 1984.
172. Iwahashi, H.; Morishita, H.; Toshihiro, I.; Sugata, R.; Kido, R. Enhancement by catechols of hydroxyl-radical formation in the presence of ferric ions and hydrogen peroxide. *1. Biochem.* 105:429-434; 1989.
173. Rao, G. S.; Pandya, K. P. Release of 2-thiobarbituric acid-reactive products from glutamate or deoxyribonucleic acid by 1,2,4-benzenetriol or hydroquinone in the presence of copper ions. *Toxicology* 59:59-65; 1989.
174. Kawanishi, S.; Inoue, S.; Kawanishi, M. Human DNA damage induced by 1,2,4-benzenetriol, a benzene metabolite. *Cancer Res.* 49:164-168; 1989.
175. Lewis, J. G.; Stewart, J. G.; Adams, D. O. Role of oxygen radicals in induction of DNA damage by metabolites of benzene. *Cancer Res.* 48:4762-4765; 1988.
176. Pandya, K. P.; Rao, G. S.; Khan, S.; Krishnamurthy, R. Accumulation of low molecular weight (bleomycin detectable) iron in bone marrow cells of rats after benzene exposure. *Arch. Toxicol.* 64:339-342; 1990.
177. Ibrahim, N. G.; Lutton, J. D.; Levere, R. D. Benzene modulation of bone marrow hematopoietic drug metabolizing systems. *Biochem. Arch.* 1:85-96; 1985.
178. Stocker, R. Induction of haem oxygenase as a defense against oxidative stress. *free Rad. Res. Commun.* 9:101-112; 1990.
179. Maines, M. D. Heme oxygenase: Function, multiplicity, regulatory mechanisms and clinical applications. *FASEB J.* 2:2557-2568; 1988.
180. Pellack-Walker, P.; Walker, J. K.; Evans, H. H.; Blumer, J. L. Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in LS178YS cells. *Mol. Pharmacol.* 28:560-566; 1985.
181. Yamada, M.; Mori, M.; Sugimura, T. Myeloperoxidases in cultured human promyelocytic leukemia cell line HL-60. *Biochem. Biophys. Res. Commun.* 98:219-226; 1981.
182. Subrahmanyam, V. V.; Kolachana, P.; Meyer, K. B.; Smith, M. T. Bioactivation and cytotoxicity of hydroquinone in human promyelocytic leukemia (HL-60) cells. *free Radical Biol. Med.* 9 (Suppl.1): abstract no. 3.29 1990.
183. Kolachana, P.; Meyer, K. B.; Subrahmanyam, V. V.; Smith, M. T. Induction of oxidative DNA damage by benzene metab-

- olites, hydroquinone and 1,2,4-benzenetriol, in HL60 cells. *Proc. Amer. Assoc. Cancer Res.* 32: abstract no. 890; 1991.
184. Hinson, J. A.; Kadlubar, F. F. Glutathione and glutathione transferases in the detoxification of drug and carcinogen metabolites. In: Sies, H.; Ketterer, B., eds. *Glutathione conjugation: Mechanisms and biological significance*. New York: Academic Press; 1988: 235-280.
 185. Ross, D. Glutathione, free radicals and chemotherapeutic agents: Mechanisms of free-radical induced toxicity and glutathione-dependent protection. *Pharmacol. Therap.* 37:231-249; 1988.
 186. Wardman, P. Conjugation and oxidation of glutathione via thiol free radicals. In: *Glutathione conjugation: Mechanisms and biological significance*. Sies, H.; Ketterer, B., eds. New York: Academic Press; 1988:43-72.
 187. Dauterman, W. C. Metabolism of toxicants: Phase II reactions. In: Hodgson, E.; Guthrie, F. E., eds. *Introduction to biochemical toxicology*. New York: Elsevier; 1982:92-105.
 188. Jerina, D.; Witkop, D. B.; Zaltzman-Nirenberg, P.; Udenfriend, S. Role of the arene-oxide-oxepin system in the metabolism of aromatic substrates: 1. In vitro conversion of benzene oxide to a mercapturic acid and a dihydrodiol. *Arch. Biochem. Biophys.* 128:176-183; 1968.
 189. Nerland, D. E.; Pierce, W. M. Identification of N-acetyl-S-(2,5-dihydroxyphenyl)-L-cysteine as a urinary metabolite of benzene, phenol and hydroquinone. *Drug Metab. Dispos.* 18: 958-962; 1990.
 190. Subrahmanyam, V. V.; McGirr, L. G.; O'Brien, P. J. Oxygen activation during drug metabolism. *Pharmacol. Therap.* 33:63-72; 1987.
 191. Smart, R. C.; Zannoni, V. G. Effect of ascorbate on covalent binding of benzene and phenol metabolites to isolated tissue preparations. *Toxicol. Appl. Pharmacol.* 77:334-343; 1985.
 192. Sevanian, A.; Hochstein, P. Mechanisms and consequences of lipid peroxidation in biological systems. *Ann. Rev. Nun.* 5:365-390; 1985.
 193. Halliwell, B.; Gutteridge, J. M. C., eds. Lipid peroxidation: A radical chain reaction. In: *Free Radical Biol. Med.* 139-189; 1985.
 194. Marnett, L. J. Peroxyl free radicals: Potential mediators of N-mor initiation and promotion. *Carcinogenesis* 8:1365-1373; 1987.
 195. Brooks, B. R.; Klamerth, O. L. Interaction of DNA with bifunctional aldehydes. *Eur. J. Biochem.* 5:178-182; 1968.
 196. Sodem, R. S.; F.-L. Chung. 1,N²-ethenodeoxyguanosine as a potential marker for DNA adduct formation by trans-4-hydroxy-2-nonenal. *Cancer Res.* 48:320-323; 1988.
 197. Stone, K.; Kseratti, M. B.; Marnett, L. J. Investigation of the adducts formed by reaction of malondialdehyde with adenosine. *Chem. Res. Toxicol.* 3:33-38; 1990.
 198. Stone, K.; Uzierlo, A.; Marnett, L. J. Studies of the reaction of malondialdehyde with cytosine nucleosides. *Chem. Res. Toxicol.* 3:465-472; 1990.
 199. Baumann, J.; Just, I.; Wurm, G. Oxidation of suitable drugs by horseradish peroxidase/hydrogen peroxide results in the oxygenation of arachidonic acid to form hydroperoxyeicosatet-

raenoic acids in a reverse co-oxidation process. *Agents and Actions* 17:392-394; 1988.

ABBREVIATIONS

- AA — Arachidonic acid
 1,2-BO — 1,2-Benzoquinone
 1,4-BQ — 1,4-Benzoquinone
 BT — 1,2,4-Benzenetriol
 BZ — Benzene
 CAT — Catechol
 DMPO — 5,5-Dimethyl-1-pyrroline-N-oxide
 DNA — Deoxyribonucleic acid
 EPO — Eosinophil peroxidase
 GSH — Reduced glutathione
 GSSG — Oxidized glutathione
 HL-60 — Human promyelocytic leukemia cells
 H₂O₂ — Hydrogen peroxide
 HPLC — High pressure liquid chromatography
 HQ — Hydroquinone
 HRP — Horseradish peroxidase
 HBQ — 2-hydroxy, 1,4-benzoquinone
 HSQ — 2-hydroxy, 1,4-benzosemiquinone anion radical
 MPO — Myeloperoxidase
 1,2-SQ^{•-} — 1,2-Benzosemiquinone anion radical
 1,4-SQ^{•-} — 1,4-Benzosemiquinone anion radical
 t,t-MA — trans,trans-muconaldehyde
 NADPH — Reduced nicotinamide adenine dinucleotide phosphate
 NOE — Nuclear overhauser effect
 O₂^{•-} — Superoxide anion radical
 HO[•] — Hydroxyl radical
¹O₂ — Singlet oxygen
 8-OHdG — 8-hydroxy-2'-deoxyguanosine
 PGG₂ — 15-hydroperoxy-9,11-endoperoxide
 PGH₂ — 15-hydroxy-9,11-endoperoxide
 PGS — Prostaglandin H synthase
 PMA — Phorbol myristate acetate
 RNA — Ribonucleic acid
 SIRS — Soluble immune response suppressor
 SOD — Superoxide dismutase
 TBA — Thiobarbituric acid